Mechanisms for Arsenic-Stimulated Sinusoidal Endothelial Cell Capillarization by Straub, Adam C.
 MECHANISMS FOR ARSENIC-STIMULATED SINUSOIDAL ENDOTHELIAL CELL 
CAPILLARIZATION 
 
 
 
 
 
 
by 
Adam C. Straub 
B.S. Allegheny College, 2003 
 
 
 
 
 
 
 
 
 
 
Submitted to the Graduate Faculty of 
The Graduate School of Public Health in partial fulfillment  
of the requirements for the degree of 
Doctor of Philosophy 
 
 
 
 
 
 
 
 
 
University of Pittsburgh 
2008 
 
 ii 
UNIVERSITY OF PITTSBURGH 
The Graduate School of Public Health 
 
 
 
 
 
 
 
 
This dissertation was presented 
 
by 
 
 
Adam C. Straub 
 
 
 
It was defended on 
September, 4th 2008 
and approved by 
Thesis Advisor: Aaron Barchowsky, PhD, Associate Professor, Department of Environmental 
and Occupational Health, Graduate School of Public Health, University of Pittsburgh 
 
Claudette St. Croix, PhD, Assistant Professor, Department of Environmental and 
Occupational Health, Graduate School of Public Health, University of Pittsburgh  
 
Bruce Pitt, PhD, Professor and Chairman, Department of Environmental and Occupational 
Health, Graduate School of Public Health, University of Pittsburgh 
 
Donna Beer Stolz, PhD, Assistant Professor, Department of Cell Biology and Physiology, 
School of Medicine, University of Pittsburgh 
 
 
 
 
 iii 
  
Copyright © by Adam C. Straub 
2008 
 iv 
 
Abstract 
The vascular effects of arsenic in drinking water are a global public health concern that 
contribute to disease in millions of people worldwide. However, the cellular and molecular 
mechanisms for these pathogenic effects of arsenic are not well defined.   This dissertation 
examined the hypothesis that arsenic stimulates pathogenic signals through surface receptors on 
liver sinusoidal endothelial cells (LSECs) to stimulate NADPH oxidase (NOX) activity that is 
required for arsenic-stimulated LSEC capillarization.  In mice and isolated LSECs, we 
demonstrated that exposure to arsenic promoted capillarization and increased expression of 
platelet endothelial cell adhesion molecule (PECAM-1) through a time and dose dependent 
mechanism.   
Superoxide generating NOX enzyme complexes participate in vascular remodeling and 
angiogenesis and are central to arsenic stimulated cell signaling.  LSEC arsenic exposure 
increased NOX dependent superoxide generation that was inhibited using gp91ds-tat protein, 
NSC23766, a Rac1-GTPase inhibitor, or quenched by the intracellular superoxide scavenger, 
Tempol.  These inhibitors also blocked arsenic-stimulated LSEC PECAM-1 expression and 
defenestration.   In vivo arsenic exposures failed to promote LSEC capillarization in p47
phox
 
knockout mice.  These data demonstrated that arsenic stimulates capillarization through a NOX 
dependent mechanism.   
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Given that arsenic rapidly activates NOX in vascular cells, we hypothesized that 
signaling for these responses was receptor mediated.  Since arsenic-stimulated LSEC 
defenestration and capillarization is Rac1 and NOX dependent, we examined whether a g-protein 
coupled receptor (GPCR) upstream of Rac1 initiated these effects.  Pre-treatment LSECs with 
Pertussis toxin (PTX), an inhibitor of Gi/o, prevented arsenic-stimulated defenestration.   Since 
capillarization is a gain in barrier function, LSEC expression of the sphingosine-1-phosphate 
type 1 (S1P1) receptor, a major Gi/o linked regulator of endothelial barrier function, and its role 
in arsenic-stimulated defenestration were investigated.  S1P1 was highly expressed in LSECs 
relative to large vessels. In ex vivo studies, inhibiting LSEC S1P1 with a selective antagonist, 
VPC23109, blocked arsenic-stimulated superoxide generation, defenestration, and PECAM-1 
expression.  These data demonstrated that arsenic targets a specific LSEC GPCR to promote 
vascular remodeling, and the first demonstrating that S1P1 regulates oxidant-dependent LSEC 
capillarization.  Taken together, these data demonstrate that S1P1 activated NOX stimulates 
LSEC capillarization, which aids in our understanding of mechanisms underlying arsenic-
induced liver disease.    
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FOREWARD 
This project began as an investigation of the mechanisms of adverse effects of arsenic on 
liver vascular remodeling.  Analysis of epidemiology data had demonstrated that arsenic was 
strongly associated with the risk for developing cardiovascular and liver disease.  However, the 
liver stood out from other organs, since it is the primary organ that metabolizes arsenic and is the 
first organ targeted by arsenic.  In general, arsenic targets the microvasculature and vascular 
channeling and remodeling had been observed in livers of exposed individuals. Previous work in 
this laboratory focused on mechanisms of how arsenic stimulated adverse cell signaling in large 
vessel endothelial and smooth muscle cells. Little emphasis was focused on the molecular 
mechanisms of arsenic toxicity in a microvascular bed and effects in the liver vasculature were 
unknown.  Prior this investigation, the cellular and molecular mechanisms through which arsenic 
induced pathogenic changes in the liver vasculature had not been reported.   
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1.0  CHAPTER 1.   INTRODUCTION 
1.1 ARSENIC OVERVIEW 
1.1.1 The Chemistry and Distribution of Arsenic in the Environment 
Arsenic is the 33
rd
 element listed on the periodic table and naturally occurs as the 
twentieth most abundant element in the earth’s crust.  Arsenic is a metalloid that is most 
commonly found in inorganic forms and is concentrated on the earth surface at approximately 
1.5 to 2 parts per million (9).  Therefore, it is relative scarce.  Arsenic compounds can be 
classified into three major groups; inorganic arsenic compounds, organic arsenic compounds, or 
arsine gas.  Dependent upon environmental conditions, inorganic arsenic can exist in four 
valence states (-3,0,+3, and +5).  In oxidizing conditions arsenic exists as compounds called 
arsenates (e.g. As(V)) whereas in mildly reducing conditions arsenic compounds are called 
arsenites (e.g. (As(III)) (53).  The trivalent and pentavalent forms are the most common 
oxidation states. Arsenic rarely occurs in elemental form and is often found in its native form or 
as an alloy highly associated with sulfide deposits.  Inorganic arsenic often complexes with 
copper, lead, iron, nickel, cobalt, silver, thallium and other metals yielding more than 245 
mineral forms of arsenic (9).  The most common organic arsenic compounds are arsanilic acid, 
methylarsonic acid and dimethylarsinic acid, where as the most common inorganic compounds 
 2 
exist as arsenic trioxide, sodium arsenic, and arsenates (e.g. lead arsenate) (174).  Dependent 
upon the pH and the presence of other substances, interchanges of valence states may occur (64).  
Figure 1 highlights the behavior of arsenic at various oxidation-reduction states (Adapted from 
(81)). 
 
 
Figure 1.  Behavior of arsenic at various oxidation-reduction states. 
 (Eh) pH combinations. ORP = oxidation reduction potential; AsO4 = arsenate compounds; 
AsO3 = arsenite compounds; AsS2 = arsenic disulfide compounds; As = elemental arsenic; and 
AsH3 = arsine (81). 
 
Sandstones, shales, and coal contain higher than average levels of arsenic in comparison 
to sediments (9).  Soil concentrations average approximately 5 to 6 ppm, however they can range 
from 0.2 to 40 ppm among various geographic regions (81).  The most naturally occurring 
arsenic concentrations have been transported in particulate from weathered rock (1).  However, 
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in the vicinity of copper smelters levels of arsenic have been found ranging from 100-2500 
mg/kg (48). Additionally, arsenical pesticides were widely used and as a result, concentrations of 
arsenic ranging from 200-2500 mg/kg occurred in soils contaminated with pesticides (78).  
Arsenic can be released into the air from both natural and man-made sources.  The 
primary source of natural airborne arsenic is from volcanic activity, whereas man-made 
emissions primarily come from smelting of metals, combustion of fuels, and use of pesticides.  
The average level of arsenic in ambient air in the United States ranges from <1 to 3 ng/m
3
 in 
remote areas and 20 to 30 ng/m
3
 in urban areas (10).  Concentrations of arsenic in the air can 
reach several hundred nanograms per m
3 
near nonferrous metal smelters (175).  The most 
common type of arsenic found in the air is inorganic arsenic, which is primarily in particulate 
form.  Several microorganisms have been demonstrated to convert arsenic compounds into arsine 
or methyl arsine gases (33, 121).  Figure 2 highlights the many sources arsenic cycling from 
natural and anthropogenic sources (116). 
 
Figure 2.  The natural cycling of arsenic.   
Adapted from (116). 
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Naturally occurring arsenic varies in the ground water with geology and climate (15).  
Because surface and ground water are often in contact sediments and ores, waters near former 
mining or smelting sites often have high levels of arsenic.  Arsenic can occur naturally in 
geothermal springs such as areas like Yellowstone National Park, where levels can often exceed 
1 ppm (138). Sediments in rivers and lakes often have high levels of arsenic also.  Testing by the 
U.S. Geological Service has confirmed that various pockets of the U.S. have high levels of 
arsenic. Regions like New England and Maine and areas in the west including Arizona, New 
Mexico, Nevada, and Utah have high levels of arsenic (Figure 3) (22).  Worldwide, groundwater 
contamination exists in countries such as Bangladesh, India, Taiwan, Mexico, China, Argentina 
and Chile (22, 175).  In many of these areas, levels of arsenic can reach levels into the low ppm.  
 Figure 3.  Ground water levels of arsenic in the United States  
Adapted from (132). 
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1.1.2 Routes of Exposure to Arsenic 
For the general population, diet is the largest source of exposure to arsenic. Drinking 
water significantly contributes to oral intake in regions where there are high arsenic 
concentrations in well-water or in mine drainage areas.  Average levels of arsenic in the US in 
drinking water are approximately 2 µg/L or 2 ppb (57). In the US, levels of arsenic ranging from 
50-100 ppb would be considered high, with some wells showing higher concentrations including 
parts of Arizona, Utah, northern California, Oregon and Maine (22).  In 1999, WHO dropped 
their maximal contaminant level (MCL) from 50 ppb to 10 ppb.  In 2006, the EPA set the new 
MCL for arsenic at 10 ppb, replacing the previous standard of 50 ppb.    Surprisingly, seafood is 
a much larger source of arsenic compared to drinking water.  Seafood averages approximately 
<0.001 to 0.002 μg/g  of total arsenic in a market basket survey (133).  However, the form of 
arsenic in seafood is a derivative deposited into chitilagenous exoskeletons of shellfish and is not 
bioavailable to humans (93).  Rice, rice cereal, and mushrooms also contain elevated levels of 
arsenic when grown in areas irrigated with arsenic-contaminated water.  Table 1 lists the arsenic 
content in most common foods.  Feed additives or arsenic drugs administered to livestock have 
been reported to contain trace levels of arsenic (8, 28).  For females the average dietary intake of 
total arsenic is 50.6 μg/day (range of 1.01–1,081 μg/day) and for males 58.5 μg/day (range of 
0.21–1,276 μg/day) (107).   
Natural exposure to arsenic through air and soil is relatively low in comparison to food 
and water.  Particulate arsenic may be inhaled, but usually the general population exposure is 
minor.  However, high level arsenic exposures from cooking smoke have been reported in rural, 
socioeconomically depressed areas where animal dung is the main source of cooking fuel and in 
Chinese cities where cooking is done with arsenic-laden coal (122).  Drying peppers and corn 
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over these coal fires led to high levels of exposure through food that resulted in increased 
incidence of hepatocellular carcinoma in a region of China (102). In occupational settings where 
arsenic is used or released as dusts or aerosols in air, such as metal smelting, pesticide 
manufacturing or application, wood preservation, semiconductor manufacturing, or glass 
production, individuals may be exposed to substantially elevated levels of arsenic.  Tobacco 
smoke may contain some arsenic, especially in areas where plants have been treated with 
arsenic-containing insecticides or soils that have elevated levels of arsenic (81).    
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Table 1. Arsenic content of common foods. 
Adapted from (9, 81). 
Food material Arsenic ( ppm dry weight) 
 
Apples 0.04 to 1.72 
Baking powder 1.0 
Beef 0.008 
Beer 0.01 to 2.0 
Chicken 0.02 
Chocolate 0.07 to 1.53 
Crab 27.0 to 52.5 
Crawfish 12.0 to 54.6 
Eggs 0.005 
Grapes 0.75 to 1.20 
Lettuce 0.01 to 3.78 
Lima beans 0.4 
Lobster 2.27 to 54.5 
Milk 0.0005 to 0.07 
Oats <0.1 to 2.28 
Orange juice 0.008 to 0.12 
Oysters 0.3 to 3.7 
Pop corn 0.1 
Pork 0.22 to 0.32 
Potatoes 0.0076 to 1.25 
Rice grains <0.07 to 3.53 
Scallops 27.0 to 63.8 
Shrimp 1.27 to 41.6 
Soybeans 0.05 to 1.22 
Sugar 0.15 
Tomatoes 0.01 to 2.95 
Tuna 0.71 to 4.6 
Wheat flour 0.01 to 0.09 
Wine, red 0.03 to 1.38 
Wine, white 0.06 to 0.56 
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1.1.3 Toxicokinetics of Arsenic 
   Ninety percent of ingested inorganic As(III) or As(V) is absorbed through the 
gastrointestinal tract according to animal and human studies, with greater than 50% of the 
ingested arsenic excreted into the urine within the first five days (174).  Organic arsenicals that 
are in seafood are also readily absorbed at an absorption rate of approximately 75-85%, but 
almost non-toxic (174).  Forms of arsenic that are less soluble are not absorbed that readily such 
as arsenic trioxide (64).  Soils contaminated with high levels of arsenic such as those near 
smelters have less bioavailability (63).  
 Arsenic distribution in mammals generally follows that of water.  After ingestion, arsenic 
is absorbed through the gastrointestinal tract, and then is transported to the liver.  Arsenic is then 
partitioned throughout the body with blood being the primary vehicle for transport and 
distribution.  Arsenic is rapidly excreted into the urine (156).  Arsenic distribution that has 
accumulated throughout the body is largely available from autopsy data.  Lungs, kidneys, 
skeletal muscle, and kidneys have the highest absolute amounts of arsenic, whereas the skin, 
nails, and hair have the highest concentrations (174).  Autopsy data also demonstrated that 
neonates had approximately the same amount of arsenic as their exposed mother (175).  
Nevertheless, tissue distribution determined that the liver, kidneys, bile, brain, skin and blood are 
2-25 times higher for As(III) than for As(V) (3).  Data from retired metal-smelter workers 
showed that arsenic levels in the lung were eight times higher than normal individuals suggesting 
that arsenic containing compounds from the smelter environment had very low solubility and 
persisted in the lung (23).    
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 Arsenic undergoes both reductive and oxidative metabolism.  Arsenic metabolism 
primarily occurs in the liver and to a lesser extent the kidney and lungs.  Many, but not all, 
mammalian species have the ability to methylate inorganic arsenic (165).  Cullen et al (38) first 
proposed the general scheme for methylation of arsenic and is summarized in Figure 4  and 
reviewed in (156).  The preferred substrate for inorganic arsenic methylation is As(III).  
However, As(V) can be enzymatically reduced to As(III) with glutathione serving  as the 
electron donor (134).  After oxidation/reduction reactions, s-adenosylmethionine provides 
substrate in methylation reactions that generate MAs and DMAs.  In general, the lower the 
oxidation state forms provide higher levels of toxicity (156). Distribution of arsenic species in 
the urine following sub-chronic exposure to arsenic are as follows; ~21% inorganic arsenic, 
~15% MAs, and ~64% DMAs with an average urinary arsenic concentration of 4.4-57.2 g/L 
(174).   
 
 
Figure 4.  General schematic for arsenic methylation. 
Adapted from (38, 156). 
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The metabolism of arsenic has an important role in its toxicity. Given that most species 
convert inorganic arsenic to methylated species, the relative toxicity attributed to the methylated 
forms is poorly understood.  Methylated species of arsenic exert very distinct biological effects 
in various cell types Figure 5 (153). Cell culture studies have demonstrated that MA and DMA 
are more cytotoxic, genotoxic, and inhibit some enzyme activity more potently that inorganic 
arsenite (156).   
  
 
 
Figure 5.  The cytotoxicity of arsenicals in rat and human cells  
Adapted from(153). 
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Arsenic and its metabolites in the body fluids are often used as biomarkers for arsenic 
exposure.  Urine samples are the most common way to evaluate arsenic exposure, due to the ease 
of sampling and painless procedure (25).   Urinary porphyrins have also been demonstrated to be 
used as an arsenic biomarker of exposure (170). MMA and DMA are used as biomarkers of 
arsenic ingestion since arsenic is metabolized in a two-step methylation process.   Another 
commonly used biomarker for arsenic exposure is hair samples.  Since inorganic arsenic and 
DMA are deposited in the root of the hair and moves into hair shafts, hair sampling is commonly 
used. This method reflects past arsenic exposure at the time in which the hair was formed, since 
arsenic binds to sulfdryl groups on keratin and is retained throughout growth. Similarly, nails 
from fingers and toes are also used and reflect exposure over a period of time.   Also, peripheral 
blood samples can be used for evaluating arsenic exposure (70). In a study looking at blood, 
urine, and water concentrations of arsenic, all three measures significantly correlated with the 
incidence of skin lesions (70).   
1.1.4 Health Effects of Arsenic 
Arsenic has a long history of causing adverse health effects.  It is estimated over 100 
million people world-wide are exposed to arsenic in their drinking water at concentrations above 
the recommended MCL of 10 ppb (169).  The first well documented disease associated with 
drinking water contaminated with arsenic was Blackfoot Disease (BFD) (a type of 
arteriosclerosis obliterans resulting in gangrene) in Taiwan nearly a half a century ago (157, 159-
161).  Arsenic contaminated drinking water led to a massive epidemic of arsenic-related diseases 
in Bangladesh. It is estimated that 57 million people have been exposed to greater than 10 ppb in 
Bangladesh alone.  Strong epidemiological evidence has demonstrated that individuals exposed 
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to arsenic increase the risk for the development of many diseases including; hyperkeratosis, 
cancers, cardiovascular disease, liver disease, lung disease, reproduction dysfunction, and 
neurological disease (10). Animal studies have also recapitulated arsenic related diseases; 
however animals appear to be less susceptible to arsenic than humans based on LD 50 studies 
and cancer (10). However, cardiovascular effects have been demonstrated in individuals exposed 
to 50-100 ppb of arsenic (32, 126).   
 
1.1.5 Arsenic and Cardiovascular Disease 
 Chronic exposure to arsenic is associated with the development of cardiovascular disease 
(30, 117, 167).  Carotid atherosclerosis, peripheral vascular disease, ischemic heart disease, 
cerebovascular disease, QT prolongation, coronary heart disease, stroke and impaired 
microcirculation have an extensive history of being associated with arsenic exposure (117, 167).  
In the general population, these diseases are highly associated with arsenic contaminated 
drinking water, rather than inhalation exposure. The worst cardiovascular disease associated with 
arsenic is BFD; a disease that is characterized as arteriosclerosis obliterans that results in severe 
peripheral vascular disease and loss of extremities.  However, this disease is rarely seen outside 
the Taiwanese and Bangladesh populations where exposure is on the upward magnitude of 1.5 
ppm in the drinking water (2). The range of relative risks conducted in Taiwanese populations 
were as follows; ischemic heart disease  1.6-4.9, peripheral vascular disease 1.7-4.3, and stroke 
0.7-1.5 (117). In a study looking at peripheral vascular disease in a BFD-hyperendemic area in 
Taiwan, individuals with higher arsenic exposure and a lower capacity to methylate inorganic 
arsenic to DMA had an increased risk for disease development (158).  Similarly, data from a 
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Taiwan population demonstrated that inefficient arsenic methylation increased the risk for 
hypertension (76).  In addition, arsenic exposure contributes to atherogenesis with evidence of 
chronic, irreversible mural thickening and enhanced atheroma formation at levels in the ppm 
(142, 168).  Hypertension and ischemic heart disease have been strongly correlated with lower 
level exposures (50-1000ppb) in both the Asian and United States populations (29, 97, 126).  
However, chronic arsenic exposures at even the previous MCL of 50 ppb may double the risk of 
developing hypertension after chronic exposure to arsenic (126).  This was recently confirmed by 
demonstrating significant increased risk of hypertension in humans exposed to 50 ppb of arsenic 
and below, especially in those individuals with poor nutritional status (32, 115).  Tables 2,3, and 
4 examine epidemiological data looking at the association of arsenic exposure and the 
development of peripheral vascular disease, ischemic heart disease, and cerebrovascular disease 
(167).  Taken together, the data indicate that chronic exposure to arsenic increases the risk for the 
development of cardiovascular disease in a dose-dependent manner. 
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Table 2. Epidemiological studies demonstrating the risk of arsenic exposure and the 
development of peripheral vascular disease in general populations.  
Adapted from (167). 
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Table 3. Epidemiological studies demonstrating the risk of arsenic exposure and the 
development of ischemic heart disease in general populations.  
Adapted from (167). 
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Table 4. Epidemiological studies demonstrating the risk of arsenic exposure and the 
development of cerebrovascular disease in general populations.  
Adapted from (167). 
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1.1.6 Arsenic Stimulated Liver Vascular Pathology  
Arsenic is highly associated with non-cirrhotic hepatic portal fibrosis, hepatomeglia, and 
to a lesser extent portal hypertension.  Increased vascular channels and vascular shunting are 
common findings within the portal region of arsenic-exposed individuals who have developed 
these diseases (110).  Liver and cardiac disorders are also common side effects of antileukemic 
arsenite regimes (139). Accumulating evidence also suggests that arsenic could be a liver 
carcinogen (101).  Despite the association between arsenic and liver disease, mechanisms 
defining the underlying pathologies are poorly understood.  One mouse study demonstrated that 
chronic exposure (9 months) to high doses of arsenite (50-500µg/mouse/day by gavage) caused 
liver lipid peroxidation, inflammation, and cytokine release (41).  However, this would be 
equivalent to a human drinking 2-20 mg/day for approximately 26 years before inflammatory 
toxicity occurred.  This does not fit the demographic for arsenic-induced liver disease in humans, 
where increased urinary porphyrins, a biomarker for liver injury are evident in humans under the 
age of 20 (119).  In vivo, high doses of arsenic can promote hepatocyte apoptosis as well as the 
other cells in the liver (14).   Therefore, the mechanisms for the pathogenic effects of chronic 
arsenic exposure in the liver remain unresolved and there is a strong need for understanding the 
health risks from low dose arsenic exposures. 
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1.2 PHYSIOLOGY OF THE LIVER MICROVASCULATURE AND ITS ROLE IN 
 LIVER DISEASE 
1.2.1 Structure and Function of Liver Sinusoidal Endothelial Cells 
The liver sinusoids are regarded as unique capillaries that differ from all other capillary 
beds throughout the body.  Lining the sinusoids are LSECs that harbor open cytoplasm pores 
called fenestrae that are organized into sieve plates seen in Figure 6. In general, the fenestrae 
measure 150-175nm in diameter, and occur at a frequency of 9-13 per µm
2
 and occupy 6-8% of 
the endothelial cell surface (17).  However, these measures differ from periportal to centrilobular 
zones; where diameter decrease from 110.7±0.2 nm to 104.8±0.2 nm, frequency increases from 9 
to 13 per µm
2
 and porosity increases from 6-8% (176).  Other distinct features of LSECs are the 
lack of a basal lamina underneath the endothelium, and low expression of PECAM-1 and von 
Willebrand factor. LSEC fenestrations are a dynamic filtration system that serves to filter 
lipoproteins, nutrients, and macromolecules from the blood stream and allow only particles 
smaller than the fenestrae to reach the parenchymal cells or to leave the space of Disse (62, 86).  
LSEC filtering is also facilitated by a lack of a basal lamina that allows free exchange between 
blood and hepatocytes to enhance oxygenation and increase metabolism of xenobiotics.  LSECs 
also function as a highly active scavenger receptor system significantly contributing to clearance 
of modified albumin, hyaluronin, and advance glycation end products from the blood (59, 109, 
173, 183).    
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Figure 6.  The ultrastructure of LSECs. 
F-fenestration, SP-Sieve Plate, SD-Space of Disse, H-Hepatocyte, L-Lumen, N-Nucleus, E-
Endothelium 
 
1.2.2 Regulation and Maintenance of the LSEC Phenotype.   
Regulation of the LSEC phenotype is an essential process that is poorly understood.  This 
regulation is mediated by both autocrine and paracrine cell signaling.  Constitutive expression of 
VEGF in the LSEC or surrounding cells is required to maintain open fenestrations (45, 46).  
VEGF in turn stimulates endothelial nitric oxide synthase (eNOS) to produce nitric oxide (NO).  
This phenotype is likely mediated by VEGFR2, since expression of VEGFR1 in a LSEC cell line 
increased branching morphogenesis and apoptosis (87).  Overstimulation of LSECs with VEGF 
results in dilation of fenestrae (180), whereas limited VEGF promotes LSEC defenestration (46).   
Elucidation of cytosketelal proteins that regulate LSEC fenestrae has led to actin-
microfilaments near and around the fenestrae (120).  Rho-A has emerged as a potent regulator of 
F 
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the actin cytoskeleton and its regulation in cell morphology (21).  In both physiological and 
pathophysiological states, Rho A may play a role in cytoskeletal rearrangements such as 
fenestrae dilation and contraction.  Results from Yokomori et al, demonstrated that Rho A 
modulates fenestral changes in LSEC by regulating the actin cytoskeleton (181).  Taken together, 
these results indicate that both ligand induced regulation as well as cytoskeleton maintenance are 
critical for preservation of the LSEC phenotype.   
1.2.3 Capillarization and its Role in Disease. 
Vascular remodeling, angiogenesis, cell death, and extracellular matrix deposition are 
important contributors in the pathogenesis for portal hypertension, portal fibrosis and possible 
progression to hepatocellular carcinoma. (60, 69, 114, 136, 162, 171).  This type of progressive 
injury and repair can eventually comprise blood flow and liver function.  Chemical exposures 
such as chronic alcohol abuse (162) or excess environmental exposures to selenium (51) can 
enhance angiogenic changes in the liver by increasing vascular channels, increasing perfusion 
pressure, and promoting fibrosis.  In the liver, classic angiogenesis does not occur by increasing 
total number or density of blood vessels, since the liver is at maximum capacity for 
vascularization.  Rather, angiogenic changes in the liver are manifested by a differentiation 
process called capillarization or pseudocapillarization.  Capillarization is a maturation process in 
which sinusoidal endothelial cells defenestrate, develop a basement membrane, and express 
junctional PECAM-1 (17, 37, 46, 69, 162).  This process promotes the conversion of a 
discontinuous endothelium to a continuous lining of the hepatic sinusoids with tight intercellular 
junctions and limited fenestrations (17, 37, 51, 179).  As a result, solutes, macromolecules, 
chylomicron remnants and particles are inhibited from being exchanged to the Space of Disse for 
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clearance by parenchymal cells (17, 69). This decreases liver clearance of nutrients, glucose, and 
lipids to promote systemic vascular diseases and atherosclerosis (17, 34, 35, 73).  Also, 
capillarization precedes alcoholic liver disease, portal hypertension, fibrosis and chronic hepatitis 
(45, 46, 51, 98, 162, 179). LSEC capillarization increases perfusion pressure by decreasing blood 
flow through the hepatic sieve plates.  This ultimately results in inflammation, remodeling of the 
intrahepatic circulation, and fibrosis (69, 114, 162).                    
 
1.2.4 Exogenous Compounds that Alter the Dynamics of LSEC Morphology. 
Over the past 20 years, numerous physiological and pathophysiological compounds have 
been demonstrated to alter the dynamics of LSEC morphology.  Changes in response to toxins, 
hormones, drugs, and disease can profoundly lead to contraction or dilation. Table 5 adapted 
from (17) highlights the numerous agents that can alter normal LSEC morphology.  
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Table 5. List of agents that stimulate contraction or dilation of fenestrae.  
Adapted from (17). 
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1.3 MECHANISMS OF ARSENIC-STIMULATED ANGIOGENESIS AND  
  VASCULAR REMODELING 
1.3.1 NADPH Oxidase and Reactive Oxygen Cell Signaling  
Superoxide generating NOX is an essential enzyme in endothelial and smooth muscle 
cells that is fundamental to neovascularization, angiogenesis, and vessel remodeling.  Numerous 
endogenous and exogenous factors can activate NOX ( as reviewed in (104, 163).  Endothelial 
cells express NOX2 (also known as gp91
phox
) and NOX4, whereas smooth muscle cells express 
NOX1 and NOX4 (163).  The NOXs are plasma membrane bound enzymes that catalyze the 
molecular reduction of O2 to O2-˙ using NADPH as the electron donor (67, 91, 163).  Superoxide 
can be dismutated by superoxide dismutase (SOD) to form hydrogen peroxide, or it can scavenge 
nitric oxide to form peroxynitrite. Both pathways have been linked to activate cell signaling in 
both physiological and pathophysiological states (163).   NOX enzymes are well characterized 
for their function and structure in non-phagocytotic cells.  In endothelial cells the oxidase is 
constitutively activated at low levels in unstimulated cells and can be acutely activated by 
agonists such as angiotensin-2 or cytokines (67). Cytoplasmic subunits that make up the NOXs 
include; p40
phox
, p47
phox
, and p67
phox
, and the small GTPase Rac.  The membrane-bound 
cytochrome-b558 complex consists of p22
phox
 and gp91
phox
.  Contrary to neutrphil activation, 
both membrane bound and cytoplasmic subunits are preassembled in unstimulated endothelial 
cells.   The initiation of events that activate NOX are characterized by the phosphorylation of 
p47
phox
 that enables binding with p22
phox
 leading to superoxide generation (99).  A schematic of 
NOX is presented in Figure 7 (104).  
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Figure 7.  A schematic drawing of essential components of NOX  
Adapted from (104). 
1.3.2 VEGF and Reactive Oxygen Signal Pathways in Regulation of Fenestrations 
VEGF and its receptors, especially VEGFR2, are central to chemical-induced 
angiogenesis and the pathogenic collateral vessel formation in portal fibrosis (60, 114, 162).  
Both VEGFR1 and R2 play a role in development of hepatocellular carcinomas (182) and 
VEGFR2 appears to have a role in dynamic vessel remodeling in portal fibrosis and hypertension 
(60, 114).  VEGF induces fenestrations in cultured endothelial cells (58, 180) and VEGF-
stimulated NO production is essential for maintaining LSEC fenestration (46).  Paradoxical dual 
roles for VEGF receptors stimulating reactive species generation have been described for 
angiogenesis and vascular remodeling in non-hepatic vessels.  VEGF-stimulated angiogenesis 
may require either eNOS generated NO or NOX generated superoxide (66, 140, 146, 163, 184).  
Since oxidative stress suppresses eNOS and superoxide decreases NO bioavailability (52).  it 
would appear that these two actions of VEGF-stimulated oxidant or NO generation would be 
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mutually exclusive.   However, it is also possible that NOX generated superoxide dismutes to 
H2O2, which then activates eNOS through a tyrosine kinase-dependent PI3K/Akt mechanism 
(52).  VEGF receptor-stimulated reactive species generation, antioxidant expression, as well as 
control of cell proliferation and migration in angiogenesis require distinct cellular localization 
and interactions of small monomeric Rho-GTPases (4, 21, 52).  The RhoA-GTPase is required 
for VEGFR2-mediated tyrosine phosphorylations (66), and is responsible for stabilizing capillary 
tube networks (42).  In contrast, Rac1 links VEGF receptors to NOX activation (4, 163, 164) and 
initiation of lumen formation in angiogenesis (42).  Rac1 regulates vessel maturation and cell 
spreading on newly formed matrix (21).  Regulation of cytoskeletal architecture by RhoA and 
Rac1 can be both complementary and opposing (21).  Rho-GTPases may affect LSEC 
architecture (181) however, the pathogenic effects of arsenic on Rho-GTPases in LSEC are 
completely unknown.  
1.3.3 Intracellular Effects and NOX Stimulation after Arsenic Exposure 
Exposure of cells to arsenic elicits a wide range of intracellular signaling pathways that is 
highly dependent upon dose, time, and cell type.  A great deal of controversy in the literature is 
caused by the failure to examine relative environmental exposures in a dose and time dependent 
manner.  Chronic arsenic exposure in human populations results in typical blood concentrations 
ranging from 0.1-1.0µM (79).  Concentrations of arsenic between 0.5 and 5 µM activate cell 
signaling in vascular cells and stimulate proliferation in confluent endothelial cells (11, 13). In 
contrast, concentrations above 5 µM are toxic to endothelial cells, however SMC are more 
resistant (29, 47, 50, 129, 148).   
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Despite their varied responses to arsenic, a few generalized observations can be 
concluded from the literature in regards to vascular cells.  Arsenic has a strong affinity for 
proteins with sulfur containing groups such as cysteines can alter signaling responses (156).   
Arsenic stimulates NOX to increase reactive oxygen formation and decreases nitric oxide levels 
in both endothelial and SMCs (12, 24, 95, 105, 106, 145).  Stimulation of reactive oxygen 
species promotes tyrosine phosphorylation in endothelial cells primarily through hydrogen 
peroxide cell signaling (11, 145) and may promote DNA adduct formation in SMCs (105).   
Arsenic may also cause cellular damage by stimulating superoxide that can scavenge nitric oxide 
to form peroxynitrite (24).  Reactive oxygen signaling can promote downstream events such as 
activation of Src tyrosine kinase (29, 143), MAP kinase activity (103), and protein kinase Cδ 
(148).  Some of these responses, such as Src activation may be secondary to arsenic stimulated 
reactive oxygen (13).  Activation of these kinases have been demonstrated to activate 
transcription factors such as NF-κB (11, 13), thereby driving the transcription of pro-angiogenic 
genes such as IL-8, Col-1 (80, 84, 148, 177).  A schematic drawing of arsenic cell signaling is 
presented in Figure 8 (Barchowsky).   
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Figure 8.  Schematic drawing of signaling events induced by arsenic.  
Adapted from Aaron Barchowsky. 
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1.4 GTPASE ACTIVITY IN RESPONSE TO ARSENIC  
1.4.1 GTPase activity in Mediating Vascular Responses to Arsenic.   
Like VEGF, arsenic stimulates the angiogenic signaling in cultured cells and 
neovascularization in vivo (11, 83, 147).  However, the signaling events for arsenic-induced 
endothelial cell activation and angiogenesis are relatively unknown.  In cultured vascular cells, 
the non-toxic effects of arsenic on reactive oxygen and nitrogen species generation (12, 13, 145)  
occur within seconds to minutes of exposure.  This implies that arsenic acts at proximal steps in 
signal amplification to stimulate endothelial cells.  Our efforts to reveal the proximal initiation 
step in arsenic signaling have focused on the repeated observation that arsenic activates and 
mobilizes Rac1 to the cell surface (145).  Our most recent data in human microvascular 
endothelial cells demonstrate that inhibiting activation of trimeric GTPase activity with Gαi-
specific PTX prevents arsenic from both activating Rac1 and inducing IL-8 or IGF-1 gene 
expression (Barchowsky lab, unpublished data).  It is unlikely that there is an arsenic-specific 
receptor linked to Gαi.  However, arsenic may stimulate receptors by binding critical cysteines in 
GPCR, such as those for  S1P1.   
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1.5 SUMMARY AND GLOBAL HYPOTHESIS FOR THE MECHANISMS OF 
ARSENIC STIMULATED CAPILLARIZATION. 
Arsenic is a naturally occurring and ubiquitous element found throughout the 
environment.  The vascular effects from arsenic in drinking water are a global public health 
concern that contributes to disease in over 100 million people worldwide. Arsenic is highly 
associated with cardiac and peripheral ischemic vascular diseases, atherosclerosis, hypertension, 
and diabetes.  The mechanisms for the pathogenic effects of chronic arsenic exposures remain 
unresolved and there is a need for understanding the health risks from low dose arsenic 
exposures.  The vascular and cardiovascular effects of arsenic are recognized as being among the 
most sensitive predictors of these health risks.  However, identifying arsenic health risks and 
filling the knowledge gaps for mechanisms of arsenic action has been complicated by a lack of 
sensitive animal models to investigate the molecular pathology of arsenic-promoted diseases.  
Capillarization with defenestration of the LSECs precedes vascular remodeling and 
shunting in the pathogenesis of liver fibrosis. Capillarization leads to decreased liver metabolism 
of lipids, glucose and other nutrients and promotes atherogenesis in response to environmental 
stresses and aging.  Arsenic promotes vascular remodeling in human liver fibrosis and portal 
hypertension. Therefore, the objectives of these studies were to identify novel disease-promoting 
mechanisms for the vascular effects of arsenic.    
The global hypothesis for these studies states that arsenic signals through the 
GPCRs to stimulate NOX activity required for hepatic endothelial cell dysfunction.  Three 
specific aims were undertaken; 1) to demonstrate that arsenic stimulates hepatic endothelial cell 
capillarization in vivo and ex vivo, 2)  to demonstrate that arsenic-stimulated NOX2 superoxide 
generation decreases the bioavailability of nitric oxide required for VEGF receptor maintained 
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fenestrations, and  3) to test the hypothesis that S1P1 is required for arsenic-stimulated  NOX2 
activity to stimulate capillarization ex vivo.  The scheme in Figure 9 demonstrates our working 
hypothesis for arsenic stimulated LSEC capillarization.  Identifying these mechanisms will 
advance the molecular understanding of pathological dysregulation of fenestrated endothelium.  
This identification will also reveal targets for chemoprevention and therapies that limit 
environmentally derived vascular diseases caused by arsenic. 
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Figure 9.  Hypothetical scheme for arsenic-stimulated LSEC capillarization. 
Adapted from Aaron Barchowsky. 
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2.0  CHAPTER 2.   METHODS AND MATERIALS 
2.1 ANIMAL EXPOSURE 
Mouse exposures were performed in agreement with institutional guidelines for animal 
safety and welfare at Dartmouth College and the University of Pittsburgh. The conditions and 
results for the Dartmouth study have been published, with the exception of data in Figure 16 
(149). C57BL/6NTac male mice, ages 6-8 weeks weighing approximately 20g were obtained 
from Taconic Farms (Hudson, NY).  Standard mouse chow and drinking water solutions were 
fed ad libitum to mice housed in boxes of three.  Fresh drinking water solutions of sodium 
arsenite (Fisher Scientific, Pittsburgh, PA) were prepared triweekly using commercially bottled 
drinking water (Giant Eagle Spring Water, Pittsburgh, PA). Mice were exposed to arsenic for 1, 
2, and 5 weeks with sodium arsenite concentrations of 10, 50, 100, or 250 ppb.  Individual mouse 
consumption of arsenite was not measured, but there were no differences in water consumption, 
body weights, or liver weights between the groups (data not shown).   
C57BL/6Ai p47
phox
 knockout mice (Taconic Farms) were housed under pathogen free 
conditions in autoclaved microisolator cages with Alpha-dri bedding to reduce footpad irritation 
and edema.  The mice were treated with 380 mg of broad spectrum sulfamethoxazole-
trimethaprin antibiotic per 500 ml drinking water according to the vendor’s instructions.  
C57BL/6 mice housed in the same manner and treated with antibiotic served as controls for the 
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C57BL/6Ai p47
phox
 -/- mice.  There were no observable infections during the arsenic exposures 
or at the time of necropsy.  All water was changed three times per week to maintain effective 
concentrations of arsenite and antibiotic.   
2.2 MATRIGEL NEOVASCULARIZATION ASSAY   
In vivo Matrigel neovascularization assays were performed, as previously described (147, 
149).  Briefly, a Matrigel plug containing 50 ng/ml recombinant FGF-2 (PeproTech, Rocky Hill, 
NJ) was implanted after the mice were exposed to arsenic for 3 wk and exposures were 
continued for an additional 2 wk.  At the end of the exposures, the mice were euthanized and 
plugs were excised with a portion of adjacent skin and muscle for orientation.  The plugs were 
then fixed in 10% neutral buffered formalin, and embedded in paraffin.  One hundred micron 
thick cross sections were stained with hematoxylin and eosin for counting vessels (identified as 
cell-lined luminal structures containing red blood cells).  The results of arsenic-effects on vessel 
number in these experiments have been published elsewhere (149).   Additional thin slices were 
immunostained for CD45 positive leukocyte infiltration, essentially as described for PECAM-1 
staining (147). 
2.3 LSEC ISOLATION AND EX VIVO CULTURE.  
Non-parenchymal cells from C57BL/6 mouse livers were obtained from the laboratory of 
Dr. Timothy Billiar. The cells were isolated by standard collagenase digestion and liver cell 
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separation, as described in (130, 135). Livers were perfused with buffered collagenase to obtain a 
single cell suspension. Parenchymal cells (hepatocytes) were removed using a low speed 
centrifugation (50g). The remaining non-parenchymal cells (LSECs, Kupffer cells, and Stellate 
cells) were placed onto a two-step 25 and 50% Percoll gradients and centrifuged at 900g for 20 
min. LSECs and Kupffer cells at the 50% interface were removed and Kupffer cells were 
eliminated by selective adherence to a non-treated Petri dish.  The non-adherent fraction yielded 
approximately 0.5x10
6
 LSECs per liver with a purity of 95% fenestrated cells, as determined by 
SEM and low PECAM-1 surface expression. Approximately 5,000 LSECs were then plated onto 
0.1% gelatin (Invitrogen, Carlsbad, CA) coated coverslips and incubated overnight in MCDB-
131 (Invitrogen, Carlsbad, CA) containing 0.5% fetal bovine serum (Hyclone, Logan, Utah), 20 
ng/ml murine VEGF (PeproTech, Rocky Hill, NJ), 50 μM ascorbic acid (Sigma, St, Louis, MO) 
10 ng/mL EGF (PeproTech, Rocky Hill, NJ), 25μg/ml gentamycin (Invitrogen, Carlsbad, CA), 
and 1μg/ml hydrocortozone (Sigma, St. Louis MO.) . The following day LSEC medium was 
replaced with medium containing one half the amount of VEGF. Sodium arsenite (1-5μM) was 
added to the LSEC for 8 h and the cells were fixed and prepared for SEM or 
immunofluorescence.  All experiments were repeated three times (cells from three separate 
livers) with duplicate cultures from each mouse (n = 6 cultures).   
2.4 MODIFIED ALBUMIN SYNTHESIS.   
FITC- or biotin- labeled native or succinylated-BSA (suc-BSA) was prepared as follows. Briefly, 
a 10 molar excess of FITC (Sigma) or biotin-NHS (Pierce), freshly prepared in DMSO, was 
added into 1 ml of BSA solution (100 mg/ml in 1 M NaHCO3). The reaction was allowed to 
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proceed at 4 
o
C for 1 hr. The reaction mixture was then either thoroughly dialyzed against PBS to 
obtain labeled native BSA, or reacted with four 25 mg aliquots of succinyl anhydride at intervals 
of 15 minutes. The succinylation continued over night at 4
o
C and then the reaction mixtures were 
purified by dialysis. The degree of succinylation of free amino groups was estimated to be 90% 
by reacting the remaining NH2- groups with 2,4,6-Trinitrobenzene sulfonic acid (Pierce).   
2.5 MODIFIED ALBUMIN UPTAKE   
To demonstrate LSEC-specific uptake, either 150 mg/ kg of FITC-BSA or FITC-suc-
BSA was injected into the mouse tail vein in 200 l of saline.  After 10 minutes, livers were 
excised, fixed in 4% paraformaldehyde and sectioned for confocal microscopic analysis.  
Quantitative uptake of suc-BSA was measured in control and arsenic-exposed mice by infusing a 
mixture of FITC-labeled acetylated-LDL (BTI Technologies) and biotin-suc-BSA (150 mg/ml 
saline) into the vena cava over three minutes.  Livers were then excised, snap frozen in liquid N2, 
and sectioned.  To control for differential perfusion of liver lobes, microscopists blinded to 
treatment selected liver sections with equivalent levels of FITC-acetylated LDL fluorescence.  
Total protein was extracted from these sections and equal amounts were assayed for biotinylated-
albumin by immunoblotting.  Likewise, cultured control LSEC or LSEC exposed to arsenic for 
24 h were incubated with 20 g/ml of biotin-suc-BSA for 10 minutes, rinsed three times with 
PBS, and then extracted for total protein to determine modified albumin uptake.  Biotin in the 75 
kDa BSA protein band was detected on transfer membranes using HRP-conjugated anti-biotin 
antibody (Cell Signaling) and enhanced chemiluminescence.   
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Densities of detected protein bands were quantified using Image J software v1.28x (NIH) and 
normalized to band densities of immunodetected -actin in the same sample. 
2.6 MEASUREMENT OF TISSUE TOTAL ARSENIC LEVELS.   
Total liver arsenic was measured in the laboratory of Dr. Miroslav Styblo at the 
University of North Carolina. Hydride generation with atomic fluorescence detection following 
tissue digestion in phosphoric acid, as previously described (77). The limit of detection for 
inorganic arsenic by this analysis was 15 pg. 
2.7 IN SITU ISOLATION OF LSEC MEMBRANE PROTEINS WITH COLLOIDAL  
SILICA.  
The luminal LSEC membranes of control or arsenic exposed mice livers were isolated by 
in situ membrane density perturbation technique as previously described (150). The proteins in 
the respective membrane fractions were separated by SDS-PAGE and probed by Western 
analysis (described below) with antibodies described in Table 6 and 7. 
2.8 SCANNING AND TRANSMISSION ELECTRON MICROSCOPY.   
SEM and TEM were used to compare liver sinusoid ultrastructure between control 
C57BL/6 mice and mice exposed to arsenite in their drinking water. At the end of the exposure 
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period, three mice in each group were euthanized by IP injection of sodium pentobarbital 
(Nembutal) and opening the thoracic cavity. The livers were perfusion fixed by flushing with 10 
ml of PBS and then perfused with 10 ml 2.5% gluteraldehyde in PBS. Livers were then removed 
and immersed in 2.5% gluteraldehyde overnight at 4°C. Samples for TEM were processed as 
described previously in (130, 150, 166).  Ultrathin, 70 nm sections were imaged on a JEM 1210 
TEM (JEOL, Peabody, MA) at 80 kV.  For SEM, perfused fixed livers were sliced into 
approximately 3-mm-thick sections, prepared for imaging as described, (130, 150, 166) and 
imaged with a JSM-6330F scanning electron microscope. 
2.9 MORPHOMETRIC QUANTITATION OF FENESTRAE    
Ten SEM images from 3 control mice or 3 arsenic-exposed mice (7500x) or 5 images 
from 6 cover slips with LSECs (10,000x) were captured.  Hepatic zones 1 and 3 were identified 
based on extracellular matrix (ECM) deposition around the large vessels and visualization of bile 
ducts.  Vessels having excess ECM were considered portal veins (Zone 1) and large vessels with 
little or no ECM were considered central veins (Zone 3).   Once zones were identified, images 
from representative regions of five sinusoids in each zone were taken at approximately 100m 
from the respective large vessel.  Porosity (open area of the sinusoid wall) was calculated using 
MetaMorph software (Universal Imaging Corp, Downingtown, PA).  The total area within a 
representative region of sinusoid in μm2 was determined. Within this area, the total open area 
was quantified. Open areas of fenestrae were summed, divided by the total area, and multiplied 
by 100 to give the percent porosity.   The porosities of the five sinusoids in each zone were 
averaged to give a single value (n) per mouse.     
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2.10 IMMUNOFLUORESCENCE MICROSCOPY   
After exposures, mice were euthanized with CO2.  Livers were excised, snap frozen in 
liquid nitrogen and stored at –80oC until sectioning.  Cryostat sections (8 micron) on charged 
glass slides were fixed for 1 minute in cold methanol.  Sections were stained as previously 
described (89) using antibodies described in Table 6 and 7 and coverslipped using Fluoromount 
G (Southern Biotech, Birmingham, AL).  Fluorescent images were captured with an Olympus 
Fluoview 500 confocal microscope (Malvern, NY) or a Nikon microphot-FXL microscope, fitted 
with an Olympus CCD digital camera. 
2.11 QUANTITATIVE IMMUNOFLUORESCENCE OF SINUSOIDAL PROTEIN 
LEVELS    
Five random 400x confocal midlobular images of immunofluorescence signals in liver 
sections were captured using identical exposure times. Using MetaMorph software, images were 
color separated, changed to monochrome format and the threshold pixel values were set to equal 
levels. Pixel number per 400x field was quantified and the average percentage of positively 
fluorescent pixels per field in the five fields was calculated to give a single value per mouse. 
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2.12 MORPHOMETRIC ANALYSIS OF PBVP    
Tissue slices were co-stained for PECAM-1 and α-SMC actin.  Hepatic arteries stained 
positive for both PECAM-1 and α-SMC actin, veins were predominantly PECAM-1 positive 
with a slight amount of α-SMC actin, and lymphatic vessels stained slightly for PECAM-1 with 
no α-SMC actin.  Epifluorescent images of two portal tracts per section of normal or arsenic 
exposed livers were captured and exported to MetaMorph.  Luminal area of hepatic arteries, as 
well as wall thickness were captured and compared.  Vascularization of the PBVP was measured 
as the number of PECAM or PECAM/α-SMC actin positive luminal structures per duct wall.   
2.13 SUPEROXIDE DETECTION. 
Primary LSEC were isolated and cultured, as described above. 5μM dihydroethidium 
(DHE) (Invitrogen, Carlsbad, CA) was loaded into cells 10 min before adding arsenite. 
Quantitative immunofluorescence was used to determine changes in DHE oxidation normalized 
to percentage of nuclear pixels, as described above.  All experimental groups contained at least 
six LSEC cultures with duplicate coverslips of cells from three separate livers. 
2.14 INHIBITION OF NOX AND SUPEROXIDE 
Isolated LSECs, a 10 min exposure to 1 mM Tempol (Sigma, St, Louis, MO) was used 
to scavenge superoxide. NOX 2 was inhibited with 10 μM of gp91ds-tat (27) added 30 minutes 
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prior to arsenic exposure. Scrambled-tat peptide was used as a negative control. Rac1 was 
inhibited by overnight incubation with 50μM NSC23766 (EMD, La Jolla, CA). 
2.15 INHIBITION OF GI AND S1P1.  
 Incubation of 100ng/mL PTX was performed overnight whereas 1M VPC23019 (S1P1 
antagonist) was pre-incubated with cells 1hr before arsenic exposure in isolated LSECs.  Cells 
were either fixed for immunoflourescence, superoxide detection, or porosity changes.   
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Table 6. List of primary antibodies. 
 
Antigen Protocol 1o Antibody Source/ Dilution 
PECAM (CD31) IF 
Rat anti-Mouse CD31 (Clone-MEC13.3) BD  
Biosciences 1:100 Monoclonal Cat. No. 550274 
Laminin IF 
Rabbit anti-laminin Sigma 1:750 Polyclonal Cat. No. 
L9393 
Caveolin-1 IF 
Rabbit anti-Caveolin-1 Cell Signaling 1:300 
Polyclonal Cat. No. 3238 
Actin WB 
Mouse anti-Actin Chemicon (Clone C4) 1:1000 
Monoclonal Cat. No. MAB1501 
Rac1 WB 
Mouse anti-Rac1 (Clone- 102) Transduction 
Laboratories 1:1000 Monoclonal Cat. No. 610651 
PECAM (CD31)-FITC 
conjugated IF 
Rat anti-mouse FITC BD Biosciences 1:500 
Monoclonal  Cat. No. 558738 
PECAM-1 (CD31) WB 
Mouse anti-PECAM Santa Cruz-1:1000 monoclonal 
Cat. No. sc-46614 
Smooth Muscle Actin IF 
Rabbit anti-mouse Epitomics 1:300 monoclonal Cat. 
No. 1184-1 
Caveolin-1 WB 
Mouse anti-caveolin-1 Transduction Labs 1:500 
monoclonal Cat. No. 610407 
VE-Cadherin IF 
Rat anti-mouse VE-Cadherin BD-Biosciences 1:500 
monoclonal Cat. No. 550548 
von Willebrand Factor IF 
Rabbit anti-vWF 1:300 Chemicon polyclonal Cat. No. 
AB7356 
PDGF-R1 IF 
Rabbit  anti-PDGF-R1- Cell Signaling 1:300 
polyclonal Cat. No. 3169 
Rac1-FITC IF 
Mouse anti-Rac1-FITC conjugated Transduction 
Laboratories 1:1000 Monoclonal Cat. No. 610652 
Rho A,B,C IF/WB 
Rabbit anti-Rho 1:300 Epitomics monoclonal Cat. No. 
1667-1 
Tie-2 IF 
Rabbit-anti Tie2 1:100 Santa Cruz polyclonal Cat. 
No. sc-324 
CD45 IF 
Rat anti-mouse 1:500 BD Biosciences monoclonal 
Cat. No. 550539 
CD68 IF 
Rat anti-mouse 1:500 Serotec monoclonal Cat. No. 
MCA1957T 
VEGF-R2 IF Rat anti-mouse 1:100 Imclone monoclonal N/A 
VEGF-R1 IF Rat anti-mouse 1:100 Imclone monoclonal N/A 
CD34 IF 
Rat anti-Mouse CD34 BD  Biosciences 1:100   Monoclonal 
Discontinued 
Desmin IF 
Rabbit anti-Desmin 1:100 Sigma polyclonal Cat. No. 
D8281 
Beta-actin WB Mouse monoclonal 1:10,000 Sigma Cat. No. A5316 
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Table 7. List of secondary antibodies. 
2o Antibody Source/ Fluorophor          Dilution 
Protocol 
Goat anti-Rat Alexa 488 Invitrogen, 
Cat. No. A-11006 1:500 IF 
Goat anti-Rabbit 594 Invitrogen, Cat. 
No. A-11012 1:500 IF 
Donkey anti-Rabbit 488 Invitrogen, Cat. 
No. A-21206 1:500 IF 
Goat anti-Mouse 594 Invitrogen,  Cat. 
No. A11005 1:500 IF 
Donkey anti-Rat 594 Invitrogen, Cat. 
No. A-21209 1:500 IF 
Chicken anti-Goat 594 Invitrogen, Cat. 
No. A-21468 1:500 IF 
anti-mouse HRP   GE Healthcare Cat. 
No. NXA931 1:5000 WB 
anti-rabbit HRP  GE Healthcare Cat. 
No. NA934 1:5000 WB 
anti-biotin HRP Cell Signaling Cat. No. 
7075 1:1000 WB 
     
Nuclear Stains    
DRAQ5 Biostatus Cat. No. DR50050 1:2000 IF 
DAPI Invitrogen Cat. No. D1306 1:500 IF 
Hoechst  Sigma Cat. No. 654434 1:500 IF 
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Table 8. List of buffers. 
Buffer Formulation Protocol 
   
Transfer 
Buffer 
25mM Tris, 192 mM glycine, 20% (w/v) 
methanol, 0.01% sodium dodecyl sulfate, 
no pH adjustment WB 
TTBS 
10mM Tris-HCL, pH 8.0, 150mM NaCl, 
0.05% Tween-20 WB 
Stop Buffer 
10mM Tris HCL, pH 7.4, 10mM EDTA, 
5mM EGTA, 0.1M NaF, 0.2M sucrose, 
100microM orthovanadate, 5mM 
pyrophosphate, protease inhibitors WB 
SDS Sample 
Buffer 
62.5mM Tris-HCl, pH 6.8, 10% glycerol, 
2% SDS, 5% beta-mercaptoethanol, 
0.05% (w/v) bromophenol blue WB 
PBS 
0.136M NaCl, 0.00268M KCl, 0.008M 
sodium Phosphate, 0.002M potassium 
phosphate IF 
Cell Fixative-
IF 2% paraformaldehyde IF 
Cell Fixative-
SEM 2.5% glutaraldehyde SEM 
SDS Lysis 
Buffer 
10mM Tris, pH 7.4, 1% SDS, 1mM 
sodium orthovanidate WB 
MBS 
0.02M MES, 0.135 NaCl, 280mM 
sorbitol, pH 5.0-5.5 
Collodial Silica Membrane 
isolation 
PAA/MBS 1mg/mL PAA in MBS 
Collodial Silica Membrane 
isolation 
Lysis Buffer 2.5mM Imidizole, pH 7.0 
Collodial Silica Membrane 
isolation 
Nycodenz 
70 % (w/V) Nycodenz diluted in lysis 
buffer 
Collodial Silica Membrane 
isolation 
Colloidal 
Silica 1% colloidal sillica 
Collodial Silica Membrane 
isolation 
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2.16 SDS-PAGE AND WESTERN BLOTTING 
 SDS-PAGE was performed using LSEC membranes isolated as described above, total 
liver tissue, or total protein from ex vivo isolated LSECs.  LSEC membranes and total liver 
protein were harvested using lysis buffer (TABLE 8) and measuring using a Bradford Assay, 
(Peirce, Rockford, IL.).  Total cell lysates from isolated LSECs were harvested using boiling 2X 
SDS buffer (TABLE 8). Equal amounts of proteins from liver membranes or total liver tissue 
were diluted 1:4 using SDS sample buffer.  All proteins were resolved on a 4-12% SDS-
polyacrylamide gel (Invitrogen, Carlsbad, CA).  A prestained molecular weight ladder was 
resolved simultaneously with proteins (Invitrogen, Carlsbad, CA).   Electrophoresis was 
performed using a constant voltage of 200V until the bromophenol blue ran off the bottom of the 
gel. 
 To perform western blotting, proteins were then transferred to polyvinylidene difluoride 
membrane (PVDF, Immobilon-P, Millipore, Bedford, MA) by a semi dry transfer apparatus 
(Hoeffer Semiphor, San Fransisco, CA) at a constant current of 92 milliamps, 50V for 
approximately 1hr using transfer buffer (TABLE 8).  Membranes were incubated in 5% non-fat 
milk for 1hr at room temperature to eliminate non-specific binding of antibodies.  Primary 
antibodies (TABLE 6) were then incubated with the membrane for 1 hour at RT or overnight at 
4ºC.  The membrane was then washed 3X with TTBS (TABLE 8) and incubated with secondary 
antibody (TABLE 7) for 30min-1hr at RT.  After 3 washes with TTBS protein were visualized 
using a chemiluminescence detection kit (Perk-Elmer, Shelton, CT) and film (Roche, 
Indianapolis, IN). 
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2.17 RT-PCR   
RNA was isolated using the Trizol Method (Invitrogen, Carlsbad, CA) according to 
manufactures directions. Quantitation of RNA was determined by absorbance at 260nm and 
280nm. Total RNA (0.5µg) was reverse transcribed with MMLV (Promega, Madison, WI) in a 
mixture of oligo-dT and dNTP’s for 60min at 44ºC and the reaction was terminated by heating to 
95ºC for 10 min. PCR was performed for 30 cycles in an MJ Research PT-100 thermalcycler 
using published primer sequences from (144) for S1P1 and S1P3. S1P1 sequences are as follows; 
forward primer -5’-gccctctcggacctattagc-3’ and reverse primer 5’-gcaggcaatgaagacactca-3’.  The 
S1P3 sequences are as follows; forward primer 5’-aacagtgtggttcctcaggg-3’ and reverse primer 5’- 
ttgactagacagccgcacac-3’.  HPRT sequences were as follows; forward primer 5’-
gctggtgaaaaggacctct-3’ and reverse primer 5’-cacaggactagaacacctgc-3’.  PCR was performed in a 
volume of 50µl for 30 cycles under the following conditions; denaturation at 94ºC for 20s, 
annealing at 55ºC for 30s; extension at 72ºC for 40s.  PCR products were resolved using a 2% 
agarose gel, visualized with ethidium bromide and viewed on an ultraviolet transluminator. 
2.18 STATISTICAL ANALYSIS    
Dose and time dependent changes in mice exposed to arsenic were compared by a t-test, 
one way, or two-way  analysis of variance (ANOVA) followed by Bonferroni’s, Dunnets, 
Tukeys, or Neuman Kuells posttest for differences between treatments.  All statistical analysis 
was performed using Prizm 4.0 software (GraphPad, San Diego, CA). 
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3.0  CHAPTER 3.  ARSENIC STIMULATES SINUSOIDAL ENDOTHELIAL CELL 
CAPILLARIZATION AND VESSEL REMODELING IN MOUSE LIVER 
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3.1 ABSTRACT:  
Trivalent arsenic is a well-known environmental toxicant that causes a wide range of 
organ specific diseases and cancers.  In the human liver, arsenic promotes vascular remodeling, 
portal fibrosis, and hypertension, but the pathogenesis of these arsenic -induced vascular changes 
is unknown.   To investigate the hypothesis that arsenic targets the hepatic endothelium to initiate 
pathogenic change, mice were exposed to 0 or 250 ppb of arsenic in their drinking water for five 
weeks.  Arsenic exposure did not affect the overall health of the animals, the general structure of 
the liver, or hepatocyte morphology.   There was no change in the total tissue arsenic levels, 
indicating that arsenic does not accumulate in the liver at this level of exposure.  However, there 
was significant vascular remodeling with increased LSEC capillarization, vascularization of the 
PBVP, and constriction of hepatic arterioles in arsenic-exposed mice.  In addition to 
ultrastructural demonstration of LSEC defenestration and capillarization, quantitative 
immunofluorescence revealed increased sinusoidal PECAM-1 and laminin-1 protein expression 
suggesting gain of adherens junctions and a basement membrane.  Conversion of the LSEC to a 
capilliarized, dedifferentiated endothelium was confirmed at the cellular level with 
demonstration of increased caveolin-1 expression and LSEC caveolae, as well as increased 
membrane bound Rac1-GTPase.  In conclusion, these data demonstrate that exposure to arsenic 
causes functional changes LSEC cell signaling for sinusoidal capillarization that may be initial 
events in pathogenic changes in the liver.  
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3.2 INTRDUCTION 
The vascular effects of arsenic are a global public health concern that contribute to 
disease in tens of millions of people worldwide (117). While the role of environmental 
contaminants in the etiology of vascular diseases and in the vascular contributions to organ 
dysfunction remains poorly defined, epidemiological studies have associated arsenic exposures 
to increased risk of cardiovascular diseases (117) and vascular contributions to liver disease 
(110). Liver effects associated with arsenic in drinking water include non-cirrhotic portal fibrosis 
and to a lesser extent portal hypertension (68, 110). These pathologies involve increased vascular 
channels in the portal regions of the liver.  Higher levels of chronic arsenic consumption increase 
urinary levels of porphyrins, a biomarker for liver injury, which are more pronounced in people 
under 20 years of age (119). In addition, cardiac and liver disorders are the major side effects of 
therapeutic arsenic regimes that treat leukemias (139). Despite epidemiological evidence that the 
liver vasculature is a pathogenic target of chronic arsenic ingestion, (110) the direct effects of 
arsenic on liver vascular cells are unknown.   
In other vascular beds and isolated cell cultures, arsenic affects both endothelial and 
smooth muscle cell physiology.  Arsenic stimulates angiogenic processes in cultured endothelial 
cells and neovascularization in intact mouse and avian models (11, 83, 147, 149). These 
angiogenic effects promote tumorigenesis in mice, as well as vascular remodeling (96, 129). 
Stimulation of endothelial cell proliferation occurs at concentrations of arsenic that are not 
cytotoxic, where as higher concentrations are cytotoxic and inhibit angiogenesis in tumors (96, 
129). Arsenic stimulates cultured smooth muscle cells to proliferate and express vascular 
endothelial cell growth factor (VEGF), a primary mediator of angiogenesis (148). While these 
effects of arsenic on cells from systemic blood vessels are well recognized, there is little data on 
 49 
the affects of arsenic exposures on liver vascular remodeling or specifically on the fenestrated 
sinusoidal endothelium. 
 The LSECs are highly specialized fenestrated cells that are unique in the 
extensive heterogeneity of vascular endothelium (17). Early in development, these cells 
differentiate to lose markers of a continuous endothelium, such as junctional expression of  
PECAM-1 and a basement membrane containing the matrix protein laminin-1 (36). In the 
differentiation process, the LSEC become fenestrated to allow sieving of circulating nutrients, 
lipids, and lipoproteins for normal liver metabolism (17). The LSEC angiogenic process is 
different from angiogenesis in endothelial cells of systemic vessels, since there is no increase in 
sinusoidal vessel number or density.  Instead, LSEC angiogenesis is a dedifferentiation and 
maturation process called capillarization with diagnostic hallmarks of LSEC defenestration and 
renewed surface expression of PECAM-1 and laminin-1 proteins (17, 37, 46, 69, 162). LSEC 
defenestration and formation tight intercellular junctions limit transendothelial cell transport (17, 
37, 51, 179). Capillarization precedes vascular remodeling of other liver vessels, such as hepatic 
arterioles and PBVP, causing blood flow shunting, vascular channel formation, and eventually 
liver fibrosis (37, 46, 98). Liver angiogenesis in general is recognized as an important pathogenic 
process not only in portal fibrosis, but also in portal hypertension and progression of 
hepatocellular carcinomas (60, 114, 136, 162, 171). Finally, animal models have been used to 
demonstrate that liver capillarization impacts the systemic vasculature by decreasing liver 
metabolism of lipids, lipoproteins, and glucose to promote atherogenesis in response to 
environmental stresses and aging (17, 35, 73).  
In mouse tumors or surrogate in vivo neovascularization assays, low to moderate levels of 
arsenic (5-250 ppb) in drinking water are angiogenic (82, 149). However, arsenic effects on the 
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liver endothelium or pathogenic angiogenic processes in the liver are unknown.  The aim of this 
study was to investigate whether a chronic, human-relevant, environmental exposure to arsenic 
causes LSEC dedifferentiation and dysfunctional capillarization in intact mice.  The data indicate 
that prolonged arsenic exposure causes LSEC maturation and sustained functional changes in 
LSEC cell signaling. 
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3.3 RESULTS:  
Arsenic does not accumulate in the liver.  After 5 wk exposures, there were no obvious 
health differences between the control mice and mice that drank water containing 250 ppb 
arsenic.  The total animal weights and liver to body weight ratio did not vary (data not shown) 
suggesting that food and water intake was equal between the groups and that was no 
hepatomegalia.  There was also no increase in liver tissue levels of total arsenic in the mice fed 
arsenic-containing water (control = 3.8 + 1.3; arsenic-exposed = 2.9 + 1.4 ng/g tissue, n = 6).  
These data confirm earlier reports that arsenic does not accumulate in mouse liver until drinking 
water levels exceed 1.0 ppm.   
 
Chronic low levels of arsenic exposure induced sinusoidal capillarization.   The effects 
of arsenic exposure on the ultrastructure of the sinusoidal endothelium were examined using both 
SEM and TEM.  As seen in Figure 10, the LSEC in normal mice contain numerous sieve plates 
with open fenestrae.  The sinusoids in arsenic-exposed mice were observably defenestrated and 
the endothelium was continuous, indicating capillarization (Figure 10).  Quantitative 
morphometric analysis revealed that arsenic caused a 4-5-fold decrease in porosity (i.e. open 
space per unit area; (Figure 10 graph) in either zone 1 or 3 of the sinusoids.  The surface of the 
arsenic exposed sinusoids showed an increase in surface projections, some of which were 
microvilli from the underlying hepatocytes protruding through the LSEC fenestrae (Figure 10).  
The TEM images in Figure 11 confirm that decreased sinusoidal porosity in arsenic-exposed 
mice was paralleled by increased hepatocyte microvilli filling of the space of Disse.   Similar 
microvilli increases were attributed to a compensatory mechanism to recover lost nutrient uptake 
(17, 166).  In contrast, mitochondria and other organellar structures within the hepatocytes 
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retained normal ultrastructure.  The magnified images in Figure 11B demonstrate arsenic-
stimulated loss of fenestrations and gain of a rudimentary basement membrane.  Caveolae, sparse 
in the LSEC of control mice, were more evident in the capilliarized LSEC of the arsenic-exposed 
mice.   
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Figure 10.  Arsenic-stimulated capillarization of the liver sinusoidal endothelium. 
SEM images of sinusoidal vessels were obtained from thick sections of livers excised from 
control mice or mice exposed to 250 ppb arsenic for 5 weeks.  In the graph, data are presented as 
mean + s.d. porosity (open bars = control, closed bars = arsenic-exposed, n=3), as determined in 
experimental procedures.  Two-way ANOVA and Bonferroni’s post-test demonstrated no 
significant differences between zones, a highly significant effect of arsenic exposure relative to 
control (*** =p<0.001).  
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Figure 11.  Arsenic-stimulated capillarization, basement membrane formation, and increased 
hepatocyte microvilli. 
A. TEM images of sinusoidal vessels were captured from thick sections of livers. Representative 
images are presented with portions magnified to illustrate changes in the space of Disse (SD). (L 
= sinusoid lumen). B.  Portions of images captured at 30,000x show closure of fenestrations and 
increased caveolae (arrows) in arsenic-exposed mice.  (Bars = 500 nm) 
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Arsenic induces sinusoidal PECAM-1 and laminin-1 protein expression.   As discussed 
above, capilliarized LSEC express surface PECAM-1 and develop a laminin-1 containing 
basement membrane (17, 46, 118). Quantitative immunofluorescence measurements were used 
to determine whether the arsenic-induced ultrastructural changes observed in Figure 10 and 11 
accompanied localized increased expression of these proteins.  PECAM-1 expression was 
selectively increased in sinusoids of arsenic-exposed mice, but not in endothelium of large 
vessels, such as the portal veins (Figure 12A and B).   The apparent increase in hepatic artery 
PECAM-1 staining may have been caused by contraction of the vessel lumen (Figure 13).  
Midlobular laminin-1expression also increased (Figure 12A) and merging the red and green 
channels in Figure 12A revealed punctate laminin-1 staining (focal red staining) that is adjacent 
to the sinusoidal PECAM-1.  This may indicate that protein expression in stellate cells, which are 
a primary source of laminin-1, (37) was also stimulated by arsenic.  The stellate cells did not 
appear activated, since there was no increase in midlobular -SMC staining (data not shown).  
Quantitative analysis of the immunostained sections demonstrated that arsenic increased 
expression of both PECAM-1 and laminin-1 relative to controls (Figure 12C).  As previously 
reported, (118) the increase in PECAM-1 protein expression at the cell junctions did not 
correlate with increased PECAM-1 mRNA levels (data not shown).   
 
 
 
 
 
 
 56 
 
 
Figure 12.  Arsenic induced expression of sinusoidal PECAM-1 and laminin protein.   
A. Thin liver sections were immunostained for PECAM-1 (green channel) or laminin-1 (red 
channel).  Merged images show DRAQ 5 stained nuclei (blue channel). Representative confocal 
images were captured at 40x with a final magnification of 400x (bar = 50 m).  B. Images of 
portal vein and periportal PECAM-1 (green) and nuclear staining demonstrate PECAM changes 
in sinusoids, but not in the portal vein endothelium (L:lumen).  C. Quantitative morphometric 
analysis of midlobular PECAM-1 and laminin-1 protein staining is presented as the mean + s.d. 
percentage of total positive-staining pixels for the respective protein per 400x microscopic field 
(** = p<0.01 and * = p<0.05, n=5 mice).  
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Arsenic stimulates vascularization of the PBVP and hepatic artery contraction. The 
PBVP is often remodeled in alcohol-induced fibrosis and cirrhosis as the hepatic arterial flow 
increases to compensate for decreased portal blood flow (162). Arsenic also promoted vascular 
remodeling of the PBVP (Figure 13A-D).  Corresponding serial sections were H&E stained 
(Figure  13A and 13C) or co-stained with antibodies to endothelial cell PECAM-1 and -SMC 
actin (Figure  13B and 13D).  The fibrous septal duct wall appeared to thicken and gain 
cellularity following arsenic exposure (Figure 13C compared with 13A).  Immunofluorescent 
analysis indicated that arsenic caused more pronounced PECAM-1 and PECAM/SMC positive 
luminal structures in the septal wall (Figure 13D versus 13B).  Arsenic increased the number of 
ductal vessels in the PBVP (Figure 13E) and decreased hepatic artery luminal diameter by 3.5 
fold (Figure 13D compared to 13B and graph 13F).  
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Figure 13.  Arsenic stimulates vascularization of the PBVP and hepatic artery 
contraction. 
Serial sections were prepared from livers from control or arsenic-exposed mice.  Overlying 
sections were stained with either H&E (A,C) or immunostained for PECAM-1 (green channel) 
and -SMC actin (red channel) (B,D).  Final image magnification was 400x  (BD:biliary ducts, 
HA:hepatic arteries).  E. The mean + s.d. of PECAM positive structures (* in images B and D) 
surrounding at least two biliary ducts per section from 5 mice is presented (*** = p<0.001).  F. 
The luminal areas of hepatic arterioles were calculated.  The data are the mean + s.d. of the 
average luminal areas of at least two hepatic arterioles per section from 5 mice in each group.  
(** = p<0.01). 
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Arsenic increases caveolin-1 and membrane Rac1 protein expression in LSEC.  LSEC 
defenestration and capillarization should be associated with functional changes in cell signaling. 
Fenestrated endothelium have decreased expression of caveolin-1 and loss or fusion of caveolae 
(16, 58). To determine whether arsenic reversed suppression of LSEC caveolin-1 expression, 
liver sections were co-immunostained for caveolin-1 and PECAM-1.  The confocal images in 
Figure 14A and graph in Figure 14B confirmed that caveolin-1 expression in normal sinusoids 
is low.  Exposure to arsenic increased liver caveolin-1 expression by 5-6 fold over control and 
this increase was localized to PECAM-1 positive sinusoidal cells.  This increase in caveolin-1 
staining correlated with the increase in caveolae observed by TEM (Fig. 11).  In angiogenesis, 
Rac1-GTPase regulates endothelial cell cytoskeletal fibers to stabilize the vessel phenotype with 
tight cell associations and spreading on a laminin-1 ECM (43). Immunoblotting for Rac1 in 
LSEC plasma membranes isolated in situ demonstrated that membrane bound GTPase was 
present in LSEC from arsenic-exposed mice (Figure 15) and not in LSEC membranes from 
controls.  The data in Figure 15 also demonstrated that chronic arsenic exposure did not 
stimulate Rac1 membrane localization in other non-parenchymal cells or hepatocytes.   
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Figure 14.  Co-localization of arsenic-stimulated caveolin-1 and PECAM-1 protein 
expression. 
Sections of livers were immunostained for PECAM-1 (green channel) or caveolin-1 (red 
channel).  Nuclei were stained with DRAQ 5 (blue channel).  The white bar = 25 m.  The graph 
presents mean + s.d. percentage of caveolin-1 positive pixels per 400x microscopic field (** = 
p<0.01; n=5). 
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Figure 15.  Chronic arsenic-stimulated mobilization of Rac1 to LSEC luminal 
membranes. 
Luminal LSEC membranes of control and arsenic exposed mice were separated from total liver 
cell membranes (light fraction), as described in Experimental Procedures.  Rac1 and actin 
(loading control) abundance was measured by Western blotting. Each lane presents protein 
abundance in liver and LSEC membranes fractions from individual mice. 
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3.4 DISCUSSION: 
Environmental arsenic exposures increase the incidence of liver diseases, such as non-
cirrhotic fibrosis and portal hypertension, in humans (110). These arsenic-associated diseases 
present with liver vascular changes including increased vascular channels and arteriovenous 
shunts (110). While angiogenesis and LSEC maturation appear to play significant roles in 
disrupting sinusoidal vessels, (60, 114, 136, 162, 171) the data presented here are the first to 
demonstrate that a human relevant arsenic exposure induces capillarization and remodels the 
liver vasculature in vivo.  These vascular phenotypic changes appear to be more sensitive 
biomarkers for arsenic exposure than arsenic levels quantified from liver tissue.  These arsenic-
induced changes in an endogenous vascular bed are consistent with previous reports that sub-
chronic or chronic exposures to low to moderate levels of arsenic enhance pathological 
remodeling in surrogate neovascularization models and tumors (82, 147, 149). Decreased LSEC 
porosity and compensatory gain of caveolae represent potential mechanisms for arsenic to alter 
liver metabolism and contribute to systemic vascular diseases.  Finally, these data are the first to 
demonstrate in vivo that arsenic affects endothelial cell signaling by increasing membrane 
localization Rac1.  
The current data differ significantly from results from previous rodent studies of arsenic 
effects on the liver vasculature (41, 61, 110). The major contrast is that vascular remodeling was 
observed following chronic exposure to a moderate arsenic exposure.  One previous mouse study 
demonstrated that prolonged (9 month) exposure to high dose arsenic (50-500 g/mouse/day by 
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gavage) resulted in liver lipid peroxidation and cytokine release (41). These doses would be the 
equivalent of a human drinking 2-20 mg of arsenic /day for approximately 26 years before 
inflammatory toxicity occurred.  This does not fit the demographic of arsenic-induced liver 
disease in humans, since significant increases in urinary porphyrins, a biomarker for liver injury, 
are more readily observed in exposed humans who are under 20 years of age (119). In vivo, high 
doses of arsenic affect all cells in the liver and promote significant apoptosis in hepatocytes (18), 
and doses of arsenic in excess of 5 M are toxic to endothelial cells (11, 13, 83, 129).  It is 
possible that high level exposures elicit multiple mechanisms for toxicity that mask pathogenic 
mechanisms mediating liver diseases in response to environmentally relevant arsenic exposures.  
The current studies used ingestion of drinking water containing a dose of arsenic that is near the 
threshold for observing significant liver disease in humans (250 ppb = ~ 0.7-.9 g/mouse/day for 
5 weeks; human equivalent ~ 32 g/day for 3.75 years)  to investigate effects on the vasculature.  
Thus, the data reflect the effects of arsenic on cell phenotype rather than cell death. 
Capillarization of hepatic sinusoids results in ultrastructural phenotypic conversion to 
defenestrated endothelial cells with tight intercellular junctions (37, 51, 179). In multiple human 
and animal studies, capillarization preceded alcohol-induced liver disease, portal hypertension, 
cirrhosis, and chronic hepatitis (46, 51, 162, 179). arsenic induced LSEC PECAM-1 expression 
and laminin-1 in the basement membrane (Figure 12) and correlated directly with decreased 
porosity and increased capillarization (Figure 10 and 11).  The data in Figure 15 confirmed that 
arsenic stimulated LSEC Rac1 membrane mobilization and indicate that this localization was 
sustained in the LSEC during chronic arsenic exposure.  Since Rac1 regulates endothelial cell 
spreading on laminin-1 matrixes during angiogenic vessel maturation (43), it is possible that 
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sustained LSEC Rac1 activation indicated chronic cell signaling changes that supports 
capillarization in response to arsenic.  
Arsenic may stimulate capillarization by disrupting the LSEC signaling that maintain 
fenestrations and suppresses cell spreading.  Tonic stimulation by VEGF promotes fenestrations 
and suppresses caveolae in cultured endothelial cells and in a number of vascular beds in vivo 
(58, 108). In LSEC, this maintenance is mediated by stimulated nitric oxide (NO) synthesis (46). 
Arsenic inhibits agonist-stimulated NO synthesis in aortic endothelial cells (12), and in vivo 
exposure to arsenic limits blood vessel vasoreactivity (124). These inhibitory effects are 
mediated by arsenic-stimulated NOX generation of superoxide (12) that consumes NO (24) or by 
decreasing tetrahydrobiopterin levels required for NO synthase activity (124). The data in Figure 
6 would be consistent with an arsenic-stimulated oxidative state in the LSEC, since Rac1 is 
essential component for arsenic-stimulated endothelial cell NOX (21, 145, 163). Disrupted 
VEGF signaling may explain the increase in LSEC caveolin-1 expression (Fig 5). (58) However, 
caveolae (Figure 11) and caveolin-1 (Figure 14) may have increased to compensate for the 
reduced “passive” transendothelial transport since the LSEC porosity is significantly diminished.  
Increased LSEC caveolin-1 would further limit NO generation by sequestering and inhibiting 
endothelial nitric oxide synthase.  (137)   
In summary, these studies are the first to demonstrate that moderate environmental 
exposure to arsenic stimulates sinusoidal capillarization and vascular remodeling of the PBVP.  
These results are novel in revealing functional remodeling of an endogenous vascular bed in 
arsenic-exposed animals.  The exposures were not long enough to observe portal fibrosis or 
changes in portal blood flow; however, the observed LSEC changes were consistent with the 
pathogenesis of intrahepatic vascular disease and development of arteriovenous shunts observed 
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in arsenic-induced human liver diseases (110).  Moreover, in vivo exposure of the liver 
vasculature is a suitable model for studying arsenic-induced effects that promote both pathogenic 
vascular cell responses and liver disease.  Further studies using this model will be needed to 
identify the molecular switches through which arsenic stimulates phenotypic change in the LSEC 
without promoting hepatocyte injury.  These studies will have great impact on the understanding 
of the mechanisms for human liver and vascular diseases associated with chronic environmental 
exposures to arsenic.    
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4.0  CHAPTER 4.  LOW LEVEL ARSENIC PROMOTES PROGRESSIVE 
INFLAMMATORY ANGIOGENESIS AND LIVER BLOOD VESSEL REMODELING 
IN MICE  
This article is published in Toxicology and Applied Pharmacology 222, 327-36 (2007). 
 
. 
 
Adam C. Straub
1
, Donna B. Stolz
2
, Harina Vin
1, 2
, Mark A. Ross
2
, Nicole V. Soucy
3
, 
Linda R. Klei
1
, and Aaron Barchowsky
1*
 
 
1
Department of Environmental and Occupational Health, University of Pittsburgh 
Graduate School of Public Health. 
2
Department of Cell Biology, University of Pittsburgh School of Medicine
 
3
Department of Pharmacology and Toxicology, Dartmouth Medical School 
 
 
 
 
 
 
 
 
 67 
 
4.1 ABSTRACT: 
The vascular effects of arsenic in drinking water are global health concerns contributing 
to human disease worldwide.  Arsenic targets the endothelial cells lining blood vessels and 
endothelial cell activation or dysfunction may underlie the pathogenesis of both arsenic-induced 
vascular diseases and arsenic-enhanced tumorigenesis.  The purpose of the current studies was to 
demonstrate that exposing mice to drinking water containing environmentally relevant levels of 
arsenic promoted endothelial cell dysfunction and pathologic vascular remodeling.  Increased 
angiogenesis, neovascularization, and inflammatory cell infiltration was observed in Matrigel 
plugs implanted in C57BL/6 mice following 5 week exposures to 5-500 ppb arsenic (149).  
Therefore, functional in vivo effects of arsenic on endothelial cell function and vessel remodeling 
in an endogenous vascular bed were investigated in the liver.  Liver sinusoidal endothelial cells 
(LSEC) became progressively defenestrated and underwent capillarization to decrease vessel 
porosity following exposure to 250 ppb arsenic for 2 weeks.  Sinusoidal expression of PECAM-1 
and laminin-1 proteins, a hallmark of capillarization, was also increased by 2 weeks of exposure.  
LSEC caveolin-1 protein and caveolae expression were induced after 2 weeks of exposure 
indicating a compensatory change.  Likewise, CD45/CD68 positive inflammatory cells did not 
accumulate in the livers until after LSEC porosity was decreased; indicating that inflammation is 
a consequence and not a cause of the arsenic-induced LSEC phenotype.  The data demonstrate 
that the liver vasculature is an early target of pathogenic arsenic effects and that the mouse liver 
vasculature is a sensitive model for investigating vascular health effects of arsenic. 
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4.2 INTRODUCTION  
The vascular effects of arsenic in drinking water pose a global public health concern and 
contribute to disease in tens of millions of people worldwide (reviewed in (56, 117)).  While the 
roles of environmental contaminants in the etiology of vascular diseases and in the vascular 
contributions to organ dysfunction remain poorly defined, epidemiological studies have 
associated arsenic exposures with increased risk of cardiovascular diseases (56, 117, 157, 178) 
and vascular contributions to liver disease (110).   Recent reports indicated that high 
environmental levels of arsenic (10-100 ppm in drinking water) accelerate atherosclerosis (24, 
141) and promote liver vascular channel formation in rodent models (110).  However, the 
number of studies that examine thresholds and mechanisms for the vascular effects of 
environmentally or human relevant arsenic exposures is limited.  This limitation is confounded 
by the current bias that intact rodent models are insensitive to the health effects of arsenic.  The 
vascular effects of arsenic are an exception since vascular activation and dysfunction occur in 
mice exposed to low ppb levels of arsenic (82, 100, 147, 149).  The importance of identifying in 
vivo endpoints that can be used to test for the vascular effects of low to moderate arsenic 
exposures is underscored by the multiple dose-dependent mechanisms elicited by arsenic 
exposures.   
Angiogenesis, neovascularization in adult tissues, is a complex process of endothelial cell 
proliferation, migration, and vessel maturation (reviewed in (26, 72)).  The majority of 
pathological angiogenesis is accompanied by recruitment of inflammatory and progenitor cells to 
elaborate growth factors and complete remodeling of the new vessel wall (131).  Thus 
endothelial cells generate the angiogenic response, but they cannot complete vessel maturation 
without recruitment of pericytes and smooth muscle cells in a process called vascular 
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myogenesis (26, 92).  Pathogenic endothelial cell activation and angiogenesis in rodent models 
are sensitive to low, environmentally relevant arsenic exposures (82, 147, 149).  Arsenic 
stimulates the angiogenic process in cultured cells and neovascularization in vivo (11, 82, 83, 
100, 147, 149). However, this stimulation occurs only at low to moderate concentrations of 
arsenic (5-500 ppb in vivo, 0.1-5.0 M in cell culture; (11, 83, 147, 149) ).  Concentrations of 
arsenic above 5 M are toxic to confluent endothelial cells and limit tube formation in culture 
(11, 129).   Arsenic is more toxic to sub-confluent endothelial cells (11) and the threshold for in 
vivo toxicity in angiogenesis assays is approximately 1-5 M (147).  In contrast, high levels of 
arsenic (10-50 M) stimulate vascular smooth muscle cells to proliferate and to increase VEGF 
expression and secretion (148).  The proliferation of the smooth muscle cells may contribute to 
the atherogenic effects and vessel dysfunction seen following arsenic exposures in humans (56, 
123).  VEGF is a primary factor for stimulating angiogenesis and plays a critical role in 
pathological angiogenesis in both atherosclerosis and tumors (5, 26, 40, 72). 
Angiogenesis is the rate limiting step in tumor growth.  As with general effects on 
vascular cells, arsenic has the dual effects on tumor angiogenesis of low dose promotion and 
high dose inhibition (82, 96, 100, 129, 147).  Depending on the tumor cell type, higher doses of 
arsenic either inhibit VEGF expression and release (129) or stimulate stress responses that 
induce VEGF (54).   Low dose arsenic exposures (5-250 ppb in drinking water, or nM to low M 
concentrations) increased neovascularization of chicken chorioallantoic membranes, stimulated 
inflammatory angiogenesis in vivo in a mouse Matrigel assay, and increased vascular density and 
vessel size in mouse tumors (82, 147, 149).  These studies indicated that vascular cells are highly 
sensitive to the effects of arsenic and that these in vivo models are useful for identifying 
mechanisms for the health effects of low dose arsenic exposures.  A deficiency in these models; 
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however, is their inability to reveal pathogenic effects of arsenic on vascular beds that are not 
developing, inflamed, or transformed. 
The unique vasculature of the liver represents an endogenous vascular bed that is a 
primary target for the pathogenic effects of arsenic.  The liver is the major organ for arsenic 
metabolism and the blood in the liver vessels should have one of the highest levels of inorganic 
arsenic and its metabolites found in the body following exposure to arsenic in drinking water.   
Liver effects associated with arsenic in drinking water include non-cirrhotic liver fibrosis and to 
a lesser extent portal hypertension (41, 68, 110).  These pathologies are distinguished by 
increased vascular channels in the portal regions of the liver.  In humans, higher levels of chronic 
arsenic consumption increase urinary levels of porphyrins, a biomarker for liver injury, that are 
more pronounced in people under 20 years of age (119).  In addition, cardiac and liver disorders 
are the major side effects of therapeutic arsenic regimes used to treat leukemia (139).   Despite 
epidemiological evidence that the liver vasculature is a pathogenic target of chronic arsenic 
ingestion  (110), the direct effects of arsenic on the liver vascular cells remain unknown.   
The filtering function of the liver sinusoids is facilitated by the specialized, highly 
fenestrated LSEC (17).   These cells are unique in the extensive heterogeneity of vascular 
endothelium throughout the body due to their role in providing low pressure transendothelial cell 
transport of nutrients and wastes into and out of the liver parenchyma (17).  Early in 
development, the LSEC differentiate to lose markers of a continuous endothelium, such as 
junctional expression of PECAM-1 and a basement membrane containing the matrix protein 
laminin-1 (36).  In the differentiation process, the LSEC gain fenestrae and gaps that allow 
sieving of circulating nutrients, lipids, and lipoproteins for normal liver metabolism (17). The 
LSEC angiogenic process is manifested differently than angiogenesis in endothelial cells of 
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systemic vessels, since there is no increase in sinusoidal vessel number or density.  Instead, 
LSEC angiogenesis is a dedifferentiation and maturation process called capillarization with 
diagnostic hallmarks of LSEC defenestration and increased surface expression of PECAM-1 and 
laminin-1 protein (17, 37, 46, 69, 162).  The normally discontinuous LSEC become a continuous 
endothelium with limited transendothelial cell transport due to loss of fenestrae and formation of 
tight intercellular endothelial junctions (17, 37, 51, 179).  Capillarization precedes vascular 
remodeling of other liver vessels, such as the hepatic arterioles and the peribiliary vascular 
plexus causing the shunting of blood flow, vascular channel formation, and eventually liver 
fibrosis (37, 46, 98).  Liver angiogenesis in general is recognized as an important factor in the 
pathogenesis not only for portal fibrosis, but also for portal hypertension and progression of 
hepatocellular carcinomas (60, 114, 136, 162, 171).  Finally, liver capillarization impacts the 
systemic vasculature by decreasing liver metabolism of lipids, lipoproteins, and glucose to 
promote atherogenesis in response to environmental stresses and aging (17, 35, 73).  Significant 
gaps remain in the mechanistic understanding of arsenic-induced endothelial cell dysfunction 
and pathogenesis of vascular diseases caused by low to moderate levels of arsenic in drinking 
water.   However, filling these knowledge gaps has been complicated by a lack of sensitive 
animal models for in vivo investigation of the molecular pathology of arsenic effects on the cells 
of endogenous vascular beds.  The objective of the following studies was to demonstrate that low 
to moderate levels of arsenic in drinking water promote inflammatory angiogenesis and vascular 
remodeling in mouse models.  The data demonstrate endothelial cell activation and inflammatory 
cell infiltration in response to as little as 50 ppb in the mouse Matrigel model.  In addition, LSEC 
undergo capillarization following sub-chronic exposure of mice to 250 ppb in drinking water.  
The data are the first demonstration of pathogenic effects of environmentally relevant arsenic 
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levels on an endogenous vascular bed and suggest that the mouse liver vasculature is a sensitive 
model for examining the vascular health effects of low dose arsenic exposures. 
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4.3 RESULTS 
Arsenic exposure enhances inflammatory angiogenesis in vivo.  Arsenic causes time- and dose-
dependent enhancement of angiogenesis in vivo in chicken chorioallantoic membrane and mouse 
Matrigel assays (147, 149).  The threshold for arsenic enhancement of FGF primed angiogenesis 
in the Matrigel assay was 5 ppb and this enhancement of angiogenic capacity was seen following 
5, 10, and 20 wk exposures to 50 and 250 ppb arsenic (149).  H&E staining of the Matrigel 
sections in this earlier study suggested that arsenic induced inflammatory cell infiltration in 
addition to increasing vascularization of the plugs (149).  To confirm this observation, the 
infiltrating cells were characterized by immunostaining thin sections of the plugs for the 
leukocyte marker CD45.  As shown in Figure 16, CD45 positive staining was only observed in 
Matrigel plugs from arsenic exposed animals and was associated with increased vascularization 
of the plugs. 
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Figure 16.  Arsenic-stimulated inflammatory cell infiltration in mouse Matrigel assays for 
neovascularization. 
Matrigel plugs were implanted subcutaneously into control mice and mice exposed for 3 weeks 
to the indicated amount of arsenite in their drinking water. Exposure was continued for an 
additional 2 weeks, and the plugs were harvested at time of euthanizing the mice. The plugs were 
fixed, embedded in paraffin, and sectioned. Overlapping sections were stained with hematoxylin 
and eosin (H&E) or immunostained for CD45-positive leukocytes (green channel). 
Immunostained sections were also stained with DRAQ 5 to visualize nuclei (blue channel). 
Arrows indicate blood vessels that are defined as luminal structures containing red blood cells 
(M = abdominal muscle). The images are representative of images from 5 animals in each group. 
 
Sub-chronic arsenic exposure induces defenestration and capillarization of liver sinusoids. 
The effects of arsenic exposure on functional morphologic change in an endogenous vascular 
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bed were investigated using SEM and TEM to examine the ultrastructure changes in mouse liver 
sinusoidal endothelium over 5 wks of exposure to 250 ppb of arsenic.  As seen in Figure 17, the 
LSEC in normal mice contain numerous sieve plates with open fenestrae (20-500 nM in 
diameter) and gaps (>500 nM in diameter).  In contrast, the sinusoids in arsenic-exposed mice 
were defenestrated and the endothelium was continuous indicating capillarization (Figure 17).  
Quantitative morphometric analysis revealed that by 2-5 wk arsenic increased the number of 
fenestrae per unit surface area of the sinusoid, but decreased the average size of the fenestrae and 
eliminated gaps to decrease overall sinusoid porosity (i.e. open space per unit area; Figure 17 
graph).  The surface of the arsenic exposed sinusoids also showed an increase in associated 
detritus and projections, some of which were microvilli from the underlying hepatocytes 
protruding through the LSEC fenestrae (Figure 17).  There were no zonal differences along the 
sinusoids for the effect of arsenic on porosity (data not shown).  The TEM images in Figure 18 
confirm that the quantitative decrease in porosity of the sinusoids in arsenic-exposed mice was 
paralleled by an increased filling of the space of Disse.   The images indicate an increased 
formation of hepatocyte microvilli and similar increases in microvilli have been attributed to a 
compensatory mechanism to recover lost nutrient uptake (17, 166).  The magnified portions of 
the TEM images showing the space of Disse demonstrate arsenic-stimulated loss of fenestrations 
and gaps and gain of a rudimentary basement membrane (Figure 18B).   
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Figure 17.  Time-dependent defenestration and capillarization of the liver sinusoidal 
endothelium after arsenic exposures. 
(A) SEM images of sinusoidal vessels were captured from thick sections of livers excised from 
control mice or mice exposed to 250 ppb arsenite in drinking water for 2 weeks. The images 
were captured at a magnification of 14,000×. (B) Sinusoid porosity (e.g. percent open space in 
the sinusoid wall) was determined in control mice and mice exposed to arsenite for 1, 2, or 
5 weeks, as described in Methods. The data in the graph present the mean ± SEM of sinusoid 
porosity of 3 mice in each group. Statistical analysis using two-way analysis of variance 
demonstrated a highly significant time effect (p < 0.01) and a significant difference in arsenic-
treated animals from control by 2 weeks (p < 0.05). 
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Figure 18.  Arsenic-stimulated capillarization, basement membrane formation, and increased 
hepatocyte microvilli. 
(A) TEM images of sinusoidal vessels were captured from  70 nm thick sections of livers from 
control mice and mice exposed to arsenite for 2 weeks (SD, space of Disse; L, sinusoid lumen). 
The images are representative of images from 3 mice in each group and do not differ from 
images of mice exposed to arsenite for 5 weeks. (B) Portions of images captured at 30,000× are 
presented to illustrate closure of fenestrations and gain in hepatocyte microvilli in the arsenite-
exposed mice, relative to control. 
 
 78 
Arsenic induces sinusoidal PECAM-1 and laminin-1 protein expression.    LSEC junctional 
expression of PECAM-1 and development of a laminin-1 containing basement membrane are 
hallmarks of capillarization and vessel maturation (17, 43, 46). Confocal microscopic image 
capture and quantitative immunofluorescence analysis for these two proteins were performed on 
frozen fixed sections to determine whether the arsenic-induced ultrastructural changes observed 
in Figure 17 and 18 were accompanied by localized increases in protein expression.  The images 
of tissue from control mice and mice exposed to arsenic for 2 wk in Figure 19A indicated that 
PECAM-1 expression was selectively increased in the sinusoids.  Consistent with the TEM 
images in Figure 18B, basement membrane laminin-1 expression also increased in the sinusoids 
of arsenic-exposed mice (Figure 19A).  Merging the red and green channels in Figure 19A 
revealed punctuate laminin-1 staining (focal red staining) that is adjacent to the sinusoidal 
PECAM-1.  This may indicate that stellate cells, a primary source of laminin-1  (37), were also 
activated by arsenic.  Consistent with the time course for loss of porosity, quantitative analysis of 
immunostained sections from mice in each exposure period demonstrated that arsenic exposure 
caused time-dependent increased expression of PECAM-1, relative to controls (Figure 19B).  As 
previously reported (118), the increase in PECAM-1 protein expression at the cell junctions did 
not correlate with changes in PECAM-1 mRNA levels (data not shown). 
 
 
 79 
 
Figure 19.  Arsenic-induced expression of sinusoidal PECAM-1 and laminin protein. 
(A) Thin sections were prepared from the livers of control mice or mice exposed to arsenite for 
2 weeks and immunostained for PECAM-1 (green channel) or laminin-1 (red channel). In the 
merged image, the blue channel was added to show DRAQ 5-stained nuclei. The representative 
confocal images were captured at 40× with a final magnification 400×. (B, C) Morphometric 
analysis of confocal immunofluorescent images was used to quantify PECAM-1 and laminin-1 
protein expression in groups of 6 mice at 1, 2, and 5 weeks. Data are expressed as the 
mean ± SEM percentage of total pixels that stain positive for the respective protein per 400× 
microscopic field. The data were analyzed by two-way analysis of variance and showed both 
significant time and treatment differences (**p < 0.01 and *p < 0.05). 
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Arsenic increases caveolin-1 and caveolae in LSEC membranes.  Fenestration of the 
endothelium is associated with a decreased expression of caveolin-1 and loss or fusion of 
caveolae (16, 58).  To determine whether arsenic reversed suppressed caveolin-1 expression in 
liver LSEC, thin sections were co-immunostained for caveolin-1 and PECAM-1.  The images 
and graph in Figure 20 confirm that caveolin-1 expression in normal sinusoids is low.  There 
was no effect of arsenic on caveolin-1 expression at early time points of exposure (Figure 20C).  
However, by wk 5 of arsenic exposure caveolin-1 protein was greatly increased.  The pattern of 
expression was highly correlated with the increase in LSEC PECAM-1 expression (Figure 20A) 
and with an increase in caveolae structures in the LSEC membranes (Figure 20B).  These data 
suggest that after the LSEC capilliarize, their phenotype continues to mature to convert from 
transporting bulk constituents through fenestrations to facilitated transendothelial transport 
through caveolae. 
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Figure 20.  Co-localization of arsenic-stimulated caveolin-1 and PECAM-1 protein expression. 
(A) Sections of livers from mice exposed to arsenite for 5 weeks or their time matched controls 
were immunostained for PECAM-1 (green channel) or caveolin-1 (red channel). In the merged 
image, the blue channel was added to show DRAQ 5-stained nuclei. The representative confocal 
images were captured at 40× magnification and magnified 10×. (B) Portions of TEM images 
captured at 30,000× are shown to present the increase in caveolae structures in the LSEC 
membrane from arsenic-exposed mice relative to controls (L, lumen; arrows point to caveolae; 
scale bars = 500 nm). (C) The graph presents quantitative morphometric analysis of the 
immunofluorescent labeled caveolin-1 in the images from 6 mice in each group. Data are 
expressed as the mean ± SEM percentage of total pixels that stain positive for caveolin-1 protein 
per 400× microscopic field (***p < 0.001). 
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Leukocyte infiltration into the liver increased following 5 wk of Arsenic exposure.  In models 
of alcohol-induced liver injury, angiogenesis and hepatic vascular remodeling are associated with 
an influx of monocytes and macrophages that deliver vascular growth and stabilizing factors 
(162).  Since arsenic increased myeloid cell infiltration in the mouse Matrigel assay (Figure 16), 
the time dependent effects of arsenic on the liver content of CD45 and CD68 positive cells was 
examined.  Consistent with the data in Figure 16, there were significant increases in both CD45 
and CD68 staining in mice exposed to arsenic for 5 wk (Figure 21).  The amount of increase in 
CD68 positive macrophages is much less striking that the increase in CD45 positive cells 
indicting that the CD68 positive population represents only a portion of the total CD45 positive 
infiltrate.  There were no differences in CD45 positive cells between control and arsenic-exposed 
mice at the earlier time points suggesting that the leukocytes are recruited after loss of porosity 
and capillarization are initiated (Figure 17).  Thus, inflammation appears to be a result and not a 
cause of arsenic-induced defenestration and capillarization. 
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Figure 21.  Arsenic-stimulated liver accumulation of CD45 and CD68-positive cells. 
Thin sections of liver from mice exposed to arsenite for the indicated time or their time matched 
controls and immunostained stained for either CD45 (leukocytes/monocytes) or CD68 
(macrophages). (A–D) Representative images of CD45- or CD68-positive staining in livers of 
5 weeks control or arsenic-exposed mice were captured at 20× and magnified by an additional 
10×. (E, F) Quantitative morphometric analysis of the immunofluorescent images from each 
treatment group was used to determine the percentage of total pixels that stained positive for 
CD45 or CD68. The graphs present mean ± SEM of values for 6 mice in each group. Two-way 
analysis of variance determined that there was a highly significant time dependence for both 
CD45 and CD68 staining, as well as significant stimulation by arsenic at 5 weeks (*p < 0.05; 
**p < 0.01). 
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4.4 DISCUSSION  
Neovascularization, angiogenesis, and vessel remodeling in the adult are fundamental to 
the pathogenesis of a number of diseases caused by environmental arsenic exposures, including 
cardiovascular ischemic diseases, atherosclerosis, tumorigenesis, and liver fibrosis.  Our previous 
studies were the first to demonstrate that exposure to arsenic in drinking water at or even below 
the current United States drinking water standard of 10 ppb enhances angiogenesis in an intact 
mouse model (149).  The data in Figure 16 extend these earlier observations by demonstrating 
that angiogenesis enhanced by 5 wk arsenic exposures is associated with recruitment of 
inflammatory cells.  This is in keeping with the pathogenesis of angiogenesis in adult tissues (26, 
39, 162).  However, these data were not unexpected, since the Matrigel plug is an inflammatory 
model primed with a threshold amount of FGF  (149).  This model is relevant to tumorigenesis 
and other studies confirm that low dose arsenic enhances the vascularization of solid tumors (82, 
100, 147).  The data in the current study go beyond these earlier studies to address the question 
of whether arsenic initiates or merely enhances pathogenic responses.  This study, therefore, is 
the first to demonstrate functional vascular changes in an endogenous vascular bed that is 
exposed to arsenic in vivo.  The data not only indicate that arsenic initiates defenestration and 
capillarization of the LSEC, but also demonstrate that arsenic-induced loss of porosity (Figure 
17) precedes inflammatory (Figure 21) and compensatory changes (Figure 20) in the sinusoidal 
endothelium. 
The data in the current study differ significantly from previous rodent studies of arsenic 
effects on the liver vasculature (14, 41, 61, 110). The major contrast is that in the current study, 
vascular remodeling was observed following sub-chronic exposure to a moderate arsenic 
exposure.  One previous study in mice demonstrated that prolonged (9 month) exposure to high 
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dose arsenic (50-500 g/mouse/day by gavage) resulted in liver lipid peroxidation and cytokine 
release (41).  Assuming equal bioavailability between species, these exposures would be the 
equivalent of a human drinking 2-20 mg of arsenic/day for approximately 26 years before 
inflammatory toxicity occurred.  This does not fit the demographic of arsenic-induced liver 
disease in humans, since significant increases in urinary porphyrins, a biomarker for liver injury, 
are more readily observed in arsenic-exposed humans who are under 20 years of age (119).  In 
vivo, high doses of arsenic affect all cells in the liver and promote a significant amount of 
apoptosis in hepatocytes (14).  High doses of arsenic (>5 M) are known to be toxic to 
endothelial cells (11, 12, 83, 129) and it is possible that high dose exposures elicit multiple 
mechanisms for toxicity that mask the pathogenic mechanisms mediating liver diseases in 
response to environmentally relevant arsenic exposures.  In contrast, the current study 
investigated effects of a relevant ad libitum ingestion of drinking water containing an arsenic 
level that was near the threshold for observing significant liver disease in humans (250 ppb = ~ 
0.7-.9 g/mouse/day for 5 weeks; human equivalent ~ 32 g/day for 3.75 years).  Thus, the data 
in this study reflect the effects of arsenic on cell phenotype rather than cell death.   
Liver injury in response to arsenic has been proposed to be mediated by oxidative stress 
and increased levels of inflammatory cytokines (41, 110).  Das et al. showed that nine months 
was required before overt liver injury was observed in response to high levels of arsenic and that 
this injury was associated with increased oxidative damage and cytokine release (41).  
Capillarization has been shown to occur with aging, an effect that may be caused by progressive 
oxidative injury to LSEC (35, 73).  The data in Figure 17 demonstrated that capillarization 
developed over 1-2 weeks of arsenic exposure and was greatly accelerated by arsenic compared 
to the natural decline in porosity seen in age matched controls.  Since arsenite stimulates oxidant 
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production by endothelial cell NOX  (145), it is possible that chronic oxidant stress was 
responsible for arsenic-induced loss of porosity and phenotypic change in LSEC.  However, if 
this was true, the oxidative stress would have had to be at a low level since total liver 
hemoxygenase-1 mRNA levels increased by less than 3-fold in following exposure to 250 ppb of 
arsenite for 5 wks (data not shown).  The data in Figure 21 argue that an inflammatory response 
resulted from arsenic-initiated capillarization instead of causing it.  Leukocytes were not 
recruited until after the maximal loss in LSEC porosity occurred.  Thus, leukocyte oxidant 
generation was unlikely to have contributed to arsenite-induced LSEC phenotypic change.   
More studies are needed to determine the threshold for arsenite stimulation of LSEC NOXs and 
whether oxidant generation accounts for the mechanism of arsenite induced pathogenic change in 
LSEC phenotype. 
Capillarization is the angiogenic process of the liver sinusoidal endothelium and is 
fundamentally different from angiogenesis in other vascular beds.  The main distinction is that 
there is no increase in vessel number due to the anatomic constraints of the liver sieve plates.  
Capillarization of LSEC results in ultrastructural phenotypic conversion to endothelial cells with 
tight intercellular junctions and loss of fenestrations (37, 51, 179).  In multiple human and animal 
studies, capillarization has been demonstrated to precede alcohol-induced liver disease, portal 
hypertension, cirrhosis, and chronic hepatitis (46, 51, 162, 179).  Increased LSEC membrane 
PECAM-1 protein expression and  deposition of a laminin-1-containing basement membrane are 
hallmarks of capillarization in injured livers (37, 46).  As seen in Figure 19, arsenic induces 
these hallmarks as it promotes defenestration and capillarization of the LSEC (Figure 17 and 
18).  The time course for gain of PECAM-1 and laminin-1 is identical to the time course for loss 
of porosity (Figure 17), indicating that these are reciprocal functions.  Thus, as the fenestrations 
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close the cells increase intracellular contacts and transport through the fenestrations is limited by 
gain of a basement membrane.  Infiltration of leukocytes, especially pro-angiogenic myeloid 
cells, is necessary for supporting pathological angiogenesis, vessel maturation, and remodeling 
(18, 26, 39, 131).  It is possible that the delayed increase in CD45 positive cell infiltration was 
the result of vessel maturation in the capillarization process rather than a direct effect of arsenic 
on leukocyte activity.  Further indication that consequential or compensatory processes continue 
to occur in the arsenite exposed mice is the gain in caveolin-1 and caveolae (Figure 20) for 
transendothelial cell transport. 
In summary, there is growing evidence that low level arsenic exposures have functional 
pathogenic consequences in endothelial cells.  Arsenic-enhanced angiogenesis occurs in mouse 
models and mouse tumors at very (82, 100, 149) making this endpoint one of the most sensitive 
reported as a health effect of arsenic in rodents.  More importantly, angiogenesis is induced in 
mice by low to moderate human relevant exposures and occurs in response to arsenic at the 
current United States MCL of 10 ppb (82, 149).  The data in the current study are the first to 
demonstrate that moderate environmental exposure to arsenite functionally affects an 
endogenous vascular bed.  While the exposures were not long enough to observe portal fibrosis 
and there was no measure of portal blood flow, the changes observed were consistent with initial 
pathogenesis of intrahepatic vascular disease and development of arteriovenous shunts in 
arsenic-induced human liver diseases (110).  The data indicate that the intact mouse and liver 
vasculature are suitable models for investigating arsenic-induced inflammatory and vascular 
changes that promote both pathogenic vascular cell responses and liver disease.  Further studies 
using this model will be needed to identify the molecular switches and mechanisms through 
which arsenic stimulates phenotypic change in the LSEC without promoting hepatocyte injury.  
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Since liver sinusoidal capillarization can contribute to atherogenic metabolic imbalance, the 
studies may have great impact on the understanding of the mechanisms for both human liver and 
vascular diseases associated with chronic environmental exposures to inorganic arsenic.    
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5.0  CHAPTER 5.  ARSENIC-STIMULATED LIVER SINUSOIDAL 
CAPILLARIZATION IN MICE REQUIRES NADPH OXIDASE-GENERATED 
SUPEROXIDE 
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5.1 ABSTRACT: 
Environmental arsenic exposure through drinking water is a significant risk factor for 
developing vascular diseases.  Human arsenic exposures cause liver portal hypertension, vascular 
shunting, and portal fibrosis through unknown mechanisms.  We hypothesized that arsenic 
exposure promotes pathogenic remodeling in LSEC that is mediated by LSEC NOX generated 
reactive oxygen species.   In these studies, exposing mice for two weeks to 10-250 ppb of 
arsenite in their drinking water caused LSEC defenestration, capillarization, increased junctional 
PECAM-1 expression, protein nitrosylation, and decreased liver clearance of modified albumin.  
In vivo arsenic exposures failed to promote LSEC morphological changes and nitrotyrosine 
formation in p47
phox
 knockout mice. These responses were caused by direct effects on LSEC 
since they were recapitulated in isolated LSEC exposed to arsenic ex vivo.  Ex vivo arsenic 
exposure increased LSEC superoxide generation that was inhibited by addition of NOX gp91ds-
tat peptide and quenched by the cell permeant superoxide scavenger, Tempol.  These two 
treatments or NSC23766, a small molecule Rac1-GTPase inhibitor, inhibited arsenic-stimulated 
LSEC differentiation and dysfunction.  These data are the first to indicate that Nox2-based 
oxidase is required for LSEC capillarization and that this oxidase has a central role in vessel 
remodeling following environmentally relevant arsenic exposures.  
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5.2 INTRODUCTION: 
Arsenic is a toxic metalloid that constitutes 0.0001% of the Earth’s crust and is a 
common contaminant of drinking water.  Drinking arsenic-contaminated water increases risk of 
cardiovascular diseases, lung disease, hepatic diseases, and cancers in millions of people world-
wide.   The World Health Organization and the United States Environmental Protection Agency 
have set the drinking water standard for arsenic at 10 ppb based on cancer risk.   However, even 
at this low level, arsenic may increase cardiovascular diseases in humans (113, 117, 186) and 
promotes angiogenesis and vascular remodeling in mice (82, 149). Epidemiological studies 
demonstrate that arsenic increases risk for many vascular pathologies including peripheral 
vascular disease, ischemic heart disease, acute myocardial infarction, atherosclerosis, and 
hypertension (31, 75, 117, 185).  In addition, vascular remodeling and shunting is commonly 
observed in arsenic-related liver diseases, such as portal hypertension and non-cirrhotic liver 
fibrosis (110).  The pathological mechanisms that contribute to angiogenesis and vascular 
remodeling in response to arsenic exposures remain unresolved. 
 
Liver LSECs are unique endothelial cells in both their architecture and function.  The 
sinusoids are the exchange vessels of the liver and the LSECs are distinguished by extensive 
fenestrations organized into sieve plates, a lack of a basement membrane, and low junctional 
expression of PECAM-1/CD31.   The LSEC architecture, including open fenestrations and weak 
junctional association between cells, provides a dynamic filtration system with low perfusion 
pressure that enables nutrients and macromolecular wastes to pass freely to hepatocytes for 
efficient metabolism.  The highly active, clathrin-mediated scavenging system in the LSEC 
contributes significantly to endocytic clearance of wastes from blood, including effective 
 92 
removal of pathogenic acylated or   glycosylated proteins (55, 59).  In addition, the LSEC are 
antigen presenting cells and interactions with LSEC and underlying hepatocyte microvilli may be 
important for naïve T-cell activation (172).  Loss of these important LSEC functions due to age 
or environmental stresses has been proposed to contribute to risk for systemic vascular diseases, 
as well as hepatic pathogenesis (44, 55, 73). 
 
The maintenance of the LSEC phenotype is a critical, but poorly understood, process that 
requires both autocrine and paracrine cell signaling.   Recent studies indicate that LSEC 
fenestrations are maintained by constitutive VEGF-stimulated NO generation in the LSEC and 
surrounding cells (46).  LSEC NO generation in turn promotes quiescence of surrounding stellate 
cells that are pro-fibrotic when activated (45).  In response to ethanol (71), oxidizing chemicals 
(35), surfactants (34), and aging (73), LSECs dedifferentiate into a more regular endothelium in 
a process termed capillarization or pseudocapillarization.  The hallmarks of capillarization are 
LSEC defenestration, development of a laminin-rich basement membrane, and junctional 
expression of PECAM.  Sinusoidal stellate cells are also induced to over-express a laminin and 
collagen matrix that contributes to fibrosis (45).  Capillarization precedes the development of 
many liver diseases including both portal hypertension and liver fibrosis.  In addition, loss of 
lipid metabolism or removal of acylated or glycolated proteins following capillarization may 
enhance atherosclerosis, insulin resistance, and possibly metabolic disease (20, 73, 111).   
Recently, environmental arsenic exposures (250 ppb) were shown to promote progressive LSEC 
capillarization in intact mice through an unresolved mechanism (151, 152). 
 
Superoxide and subsequent ROS generation by NOX-containing enzyme complexes in 
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endothelial and smooth muscle cells are fundamental to neovascularization, angiogenesis, and 
vessel remodeling caused by a variety of endogenous and exogenous factors (104, 163).  Arsenic 
stimulates NOX-based oxidase activity in cultured large vessel vascular cells (105, 145) through 
mobilization and activation of Rac1-GTPase (145) and arsenic increases Rac1 association with 
LSEC membranes during capillarization (151).  However, there are no reports of the functional 
role of this mobilization in capillarization nor are there reports of a functional role for Rac1-
stimulated LSEC NOX in capillarization in general.  The following studies investigated the 
hypothesis that arsenic stimulates LSEC Rac1 and oxidase activity to close fenestrations, 
promote capillarization, and disrupt the physiological function of scavenging modified proteins.  
The results from the in vivo experiments are the first to demonstrate that low level arsenic 
exposures stimulates dose-dependent LSEC capillarization through activation of p47
phox
-
containing NOX enzyme complexes.   Ex vivo studies in primary LSEC indicated that 
capillarization was a direct effect of arsenic on the LSEC that required Rac1.  In addition to 
identifying a novel mechanism for the vascular effects of arsenic, these studies revealed an 
essential role for Nox2-based oxidase in the pathogenesis of capillarization.     
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5.3 RESULTS: 
Arsenic stimulated dose-dependent capillarization and PECAM-1 expression in vivo 
and ex vivo.  Previous studies demonstrated that 250 ppb arsenite in drinking water resulted in 
progressive LSEC defenestration and capillarization that was maximal within 2 weeks (152).  
The data in Figure 22A demonstrate that the threshold for these pathologic changes is below the 
current MCL of 10 ppb, and that loss of porosity is dose-dependent between 10 and 100 ppb.  
The open dilated fenestrations and numerous sieve plates in control mice are lost and the 
arsenite-exposed LSEC form tighter junctions.  The loss in porosity was due to both a decrease 
in number and size of fenestrations, and as we have reported (151), there were no differences in 
the degree of arsenic effects between zones 1 and 3 of the sinusoidal beds.   Capillarization was 
confirmed in confocal images of sections stained with anti-PECAM-1 demonstrating a reciprocal 
dose-response relationship for arsenic-stimulated junctional PECAM-1 expression relative to 
porosity (Figure 23A).   As in previous studies (151, 152), there were no signs of LSEC injury 
or cell death, nor were there any signs of injury in surrounding stellate cells or hepatocytes.   
Ex vivo exposure of primary cultured LSEC to 1-5 M arsenite for 8 h recapitulated the 
in vivo observations with arsenic causing defenestration and disorganized, consolidated sieve 
plates (Figure 22B). As seen in vivo, arsenite caused a concentration-dependent increase in 
junctional PECAM-1 expression as the sieve plates were lost (Figure 23B).  These results 
demonstrate that direct LSEC effects may account for arsenite-stimulated capillarization.  
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Figure 22. Arsenite-stimulated defenestration and capillarization in vivo and ex vivo.    
A. Representative SEM images were captured from liver sections of control mice or mice 
exposed to 10-250ppb of arsenite in their drinking water for 2 weeks.  Morphometric analysis 
was used to calculate porosity (% of open space in the fenestrations relative to area of vessel 
wall) from 10 mid-lobular sinusoid vessel images from each of three separate mice per treatment 
group. Data in the graph are expressed as the mean ± SD of sinusoidal porosity and significance 
difference from control was determined using ANOVA followed by Dunnet’s post test ( ** p< 
0.01, n = 3 mice per treatment). B.  Primary cultured LSECs were exposed ex vivo to arsenite at 
the indicated concentrations for 8hrs.  Cells were fixed and processed for SEM imaging at 
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10,000x.  The data in the graph result from analysis of five images from five individual 
coverslips of cells per treatment.  The bars are mean ± sd porosity with significant difference 
from control designated by*p< 0.05, **p< 0.01 (n = 4 mice per treatment).  Bars equal 10 
micron. 
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Figure 23. Arsenite stimulated junctional PECAM-1 expression. 
A. Immunofluorescent analysis of PECAM-1 expression (green channel) and nuclei (blue 
channel) was captured from five representative mid-lobular liver sections from treated as in 
Figure 22A.  Quantitative morphometric analysis is presented in the graph as the mean  sd 
percentage of total green positive-staining pixels for PECAM-1 per 400X field.  Significant 
differences from control at * p< 0.05 or **p< 0.01 were determined using ANOVA followed by 
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Dunnet’s post test ( n = 4 mice per treatment).  B.  Isolated LSECs were treated as in Figure 
22B, fixed, analyzed by immunofluorescence imaging for PECAM-1 expression (green) and 
nuclei (blue: Draq5).  Images were captured at a magnification of 400x.  Data in the graph 
represent mean ± sd PECAM positive staining relative to Draq5 nuclei in three images from 5 
individual cultures per treatment generated from three separate livers.  Significant differences 
from control are designated by *p< 0.05 and **p< 0.01.  Bars equal 10 micron. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 99 
 
 
Arsenic decreased LSEC scavenger receptor function in vivo.   A major physiological 
role of the LSEC is scavenging of small macromolecules, such as chylomicron and derivatized 
plasma proteins (55).  Comparison of liver clearance of biotinylated-or FITC-labeled BSA or 
succinylated-BSA was used to examine whether exposure to arsenic functionally impaired 
LSEC.  Only the labeled succinylated-BSA was taken up in the liver sinusoids relative to labeled 
native BSA (Figure 24A).  The data in Figure 24B demonstrate that arsenic decreased clearance 
of biotinylated-succinylated BSA by 60% relative to untreated control mice.  A similar decrease 
was observed in isolated LSEC exposed to arsenic ex vivo (Figure 24C).  Thus, arsenic-
stimulated capillarization was associated with functional loss of physiological scavenging of 
modified proteins by the LSEC. 
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Figure 24. Arsenic inhibits LSEC scavenging of acylated protein. 
A. Mice were injected in the tail vein with either 150 mg/ kg of FITC-BSA or FITC-suc-BSA 
(green channel) in 200 l of saline.  After 10 minutes the mice were euthanized and livers were 
excised, fixed in 4% paraformaldehyde, and sectioned for confocal microscopic analysis.  
Sections were stained with rhodamine-conjugated antibody to PECAM-1 (red channel) and 
Draq5 (blue channel).  Images are representative of sections from three mice in each group.  
Abbreviations: L-large vessel; S-sinusoid vessel. Bar equals 10 microns.  B.  Three ml of FITC-
labeled acetylated-LDL and biotin-suc-BSA (150 mg/ml saline) were infused over three minutes 
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into the vena cavas of untreated mice and mice exposed to 100 ppb of arsenic for 2 wk (As).  
Livers were then excised, frozen in liquid N2, sectioned, and total protein was extracted for assay 
of retained biotin label by immunoblotting, as described in methods.  Data are presented as mean 
+ sd band density of biotin-suc-BSA normalized to -actin.  Significant difference from control 
(p< 0.01, n = 3 mice) is designated by **.  C. Isolated LSEC, incubated in the absence or 
presence of 1 mM Tempol for 10 minutes, were left untreated or exposed to 2.5 M arsenite for 
24 h.  Biotin-suc-BSA (20 g/ml) was then added for 10 min, and after rinsing, total proteins 
were extracted for Western analysis.  Data are presented as in A. * designated significant 
difference from control and ^ designates significant difference from arsenic treatment (p<0.05, n 
= 3).   
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Arsenic-stimulated capillarization is inhibited in p47
phox
 (-/-) mice.   Oxidants and 
compounds that generate oxidants promote capillarization (35, 73).  Since arsenic stimulates 
NOX-derived ROS formation in large vessel endothelial cells (145), we tested whether a similar 
mechanism mediated arsenic effects in LSEC.  Mice deficient in the canonical Nox2-based 
oxidase subunit p47
phox
 were exposed for 2 wk to 100 ppb of arsenic in their drinking water to 
test the relevance of this oxidase to capillarization in vivo.  Controls for these exposures included 
wild type and arsenite-exposed mice that were maintained on the same antibiotic and housed on 
the same bedding as the immune compromised p47
phox
 knockouts.   The data in Figure 25A 
demonstrate that sinusoids in the knockout mice do not capilliarize in response to arsenic. The 
knockout mice were also protected from other endpoints of capillarization, such as forming a 
basement membrane and increased hepatocyte microvilli in response to arsenic (Figure 25B). 
Further, arsenic-increased nitrosylation of sinusoidal proteins, an indicator of peroxynitrite 
formation, was absent in the exposed p47
phox
 (-/-) mice (Figure 26).  These results suggest that 
p47
phox
 and NOX generated superoxide contribute significantly to capillarization in vivo.    
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Figure 25.  NOX is required for arsenic-stimulated capillarization in vivo.   
Matched wildtype and p47phox knockout C57BL/6 mice were untreated or exposed to 100 ppb 
arsenite in their drinking water for 2 wk.  Liver sections were imaged by SEM at 7500x 
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magnification and porosity was quantified as in Figure 22B. Data in the graph are mean ± sd 
with significant differences determined by ANOVA followed by Newman-Keuls post test.  ** 
and ^^ designate significant difference from control or arsenite exposure, respectively (p< 0.01, n 
= 3 mice per treatment). Bar equals 1 micron.  C.  Representative TEM images of liver sinusoids 
captured from ultrathin sections of mice in A. Abbreviations: L, sinusoidal lumen; SD, space of 
Disse.  bar equals 0.1 micron. 
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Figure 26. NOX is required for arsenic-stimulated nitrotyrosine formation in vivo. 
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Frozen liver sections from mice described in Figure 25 of the main article were fixed in 2% 
paraformaldehyde and immunostained for nitrotyrosine (green channel) and PECAM-1 (red 
channel).  Nuclei were stained with Draq5 (blue channel).  The sections were imaged at 400x and 
merged to indicate the degree of co-localization of nitrosylated proteins with sinusoids.  Images 
are representative of sections of livers from three mice in each group.  Bar equals 10 microns. 
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LSEC Nox2 oxidase activity is necessary and sufficient to mediate arsenic-induced 
capillarization.  Primary LSECs in culture were exposed to arsenite ex vivo to address whether 
LSEC NOX activity was sufficient to mediate the effects of arsenic on LSEC function and 
capillarization.  First, LSEC loaded with superoxide-sensitive dihydroethidium increased their 
fluorescence (hydroethidium formation) within 30 min of arsenic exposure (Figure 27).  This 
increase followed the same concentration dependence as decreased porosity (Figure 22) or 
increased junctional PECAM-1 expression (Figure 23).  Pre-incubation of the cells with the 
superoxide scavenger Tempol prevented arsenite-increased hydroethidum fluorescence (Figure 
27), as well as loss of scavenging function (Figure 24C), decreased porosity (Figure 28), and 
increased junctional PECAM-1 expression (Figure 28).   Likewise, pre-incubation of the cells 
with gp91ds-tat peptide, an inhibitor designed to disrupt Nox2-based oxidase protein complexes 
(28), but not the scrambled-tat control peptide, prevented the arsenite-stimulated superoxide 
generation and morphologic change (Figures 27 and 28).  These results from isolated LSEC, 
combined with the results from the p47 -/- mice in Figure 25 and 26, suggest the canonical 
p47phox containing Nox2-based oxidase and its attendant superoxide generation is necessary 
and sufficient to mediate arsenite-stimulated LSEC capillarization and dysfunction. 
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Figure 27.  Arsenic-stimulated superoxide generation is inhibited by Tempol and 
gp91ds-tat peptide. 
A. Primary SECs isolated from mice were pre-loaded with 5 M dihydroethidium for 10 min 
prior to a 30 min arsenite exposure.  Cells were fixed and imaged for hydroethidium (HE; red 
channel) fluorescence and DAPI (blue channel) stained nuclei. The images are presented in grey 
scale.  B. The graph presents the mean  sd percentage of positive HE staining normalized to the 
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percentage of positive nuclei staining.  Significance difference from control, non-treated cells is 
designated by ** (p< 0.01, n = 4 cultures isolated from two livers).   C.  LSECs were pre-loaded 
with 5 M dihydroethidium with and without 1 mM Tempol 10 min prior to a 30 min a 2.5 M 
arsenite exposure and then imaged and analyzed as in B.    D.   Cells were pre-incubated with 
dihydroethidium in the presence or absence of 10 M gp91ds-tat or scrambled-tat (scrmb-tat) 
peptide for 30 minutes prior to a 2.5 M arsenite exposure.  In C. and D., significant differences 
between groups were determined by ANOVA followed by Newman-Keuls post test for multiple 
comparisons.  ** and *** designate difference from control at p< 0.01 and p< 0.001, 
respectively.   ^^^ designates significant difference from arsenite exposure (p< 0.001, C: n = 4, 
D: n = 6 cultures from three livers).  Bar equals 10 micron. 
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Figure 28.  Arsenite stimulated-defenestration and junctional PECAM-1 expression is 
inhibited by Tempol and gp91ds-tat peptide. 
Cultured LSECs were pre-incubated with Tempol, gp91ds-tat or scrambled-tat (scrmb-tat) 
peptide and then exposed to 2.5 M for 8 hours.  At the end of exposure groups of cells were 
analyzed for porosity or PECAM-1 expression changes as in Figures 22B and 23B, respectively.   
Significant differences between groups were determined by ANOVA followed by Newman-
Keuls post test.  *** and ^^^ designate significant difference from control or arsenite exposure, 
respectively (p< 0.001; n = 5 cultures from three livers).   
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Rac1-GTPase activity in arsenite-stimulated capillarization.  Rac-1 is an essential 
component of the Nox2-based oxidase required for arsenite-stimulated large vessel NOX activity 
(145). Arsenic mobilized Rac-1 to the LSEC plasma membrane during capillarization in vivo 
(151), but the function of this mobilization was unknown.  Therefore, the role of Rac1 in arsenic-
induced capillarization was tested by examining the effects of a chemical inhibitor of Rac1, 
NSC23766 (65), on arsenic-stimulated defenestration.  Overnight pre-incubation of the LSEC 
with NSC23766 prevented arsenite-reduced porosity and arsenite-increased junctional PECAM-1 
expression (Figure 29); indicating that Rac1 activity is essential for arsenite-stimulated LSEC 
capillarization.  Since NSC23766 inhibits Rac1 GTPase activity but not membrane mobilization 
(65), these data suggest that the initial step in arsenic-stimulated oxidant signaling in LSEC is 
upstream of Rac1 activation. 
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Figure 29.  Rac1 inhibition prevents arsenite-stimulated defenestration and PECAM-1 
expression. 
Cultured LSECs were incubated overnight with or without 50 M NSC23766 to inhibit Rac1-
GTPase activity.  The cells were then left untreated or exposed to 2.5 M arsenite for 8 hours.  
Cells were then fixed for SEM imaging of porosity or immunofluorescence imaging of PECAM-
1/Draq5 expression as in Figures 22B and 23B.  Significant differences between groups were 
determined by ANOVA followed by Newman-Keuls post test.  *** and ^^^ designate significant 
difference from control or arsenite exposure, respectively (p< 0.001, n = 5 cultures from three 
livers).   
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5.4 DISCUSSION 
Pathological vascular remodeling, such as neovascularization, angiogenesis, and 
morphologic changes in vascular architecture, in response to environmental insults are critical 
processes for the development of many vascular diseases including atherosclerosis, 
cardiovascular ischemic diseases, tumor vasculogenesis and liver fibrosis.  The current studies 
focused on a unique form of vascular remodeling, sinusoidal capillarization, that is known to 
pathologically compromise the LSEC and effective exchange of nutrients and wastes in the liver.   
Capillarization precedes remodeling and shunting during the progression of liver fibrosis (162, 
179), as well as allows induction of pro-fibrotic collagen expression in sinusoidal stellate cells 
(45).  Decreased liver metabolism of lipids, glucose and other nutrients promotes atherogenesis 
after capillarization in response to several environmental stressors and aging (35, 73).  We 
previously demonstrated that arsenic stimulates LSEC capillarization and remodeling of the liver 
vasculature (35, 73, 151, 152).  The current studies provide support for an arsenic-stimulated 
mechanism that requires Nox2-based oxidase generated oxidants to defenestrate and capilliarize 
LSEC, as well as impair their physiological functions.    In addition, this study is the first to 
demonstrate a functional consequence of this oxidase activity in LSEC capillarization; a process 
that has been proposed to be oxidant mediated (20, 35).   The potential public health implications 
of these findings are that they suggest that stimulation of Nox2-based oxidase in the LSEC, and 
perhaps other vascular beds, is a fundamental mechanism for the etiology of arsenic-promoted 
hepatic and systemic vascular diseases.  
 
There have been few reports of a direct physiologic or pathophysiologic role of LSEC 
oxidase enzymes.  Several studies demonstrated that oxidants, surfactants, and oxidizing 
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conditions in aging promote capillarization to alter circulating lipid and lipoprotein profiles (34, 
35, 73).  However, the mechanisms for LSEC oxidant generation other than direct chemical 
action were not investigated in these studies.   In rats, high level ethanol perfusions stimulate 
LSEC and Kupffer cell superoxide production that is inhibited by the non-selective flavoprotein 
inhibitor, diphenyleneiodonium chloride (71) and chronic co-exposures to drinking water ethanol 
and high levels (100 ppm) of injected arsenic promote oxidant-dependent vascular channeling 
and fibrosis (61).  A proposed mechanism for the observed liver pathology was depletion of 
antioxidant glutathione (61), which was unlikely to occur during the shorter and lower level 
arsenic exposures in the current study.   
 
Dorman et al. proposed that either LSEC or neutrophil Nox2 participates in sinusoidal 
injury secondary to hind limb ischemia, since gp91ds-tat protected the hepatic parenchymal and 
endothelial cells in this in vivo model from oxidative injury (49).  This model produced 
significant inflammation and much of the parenchymal injury was mediated by activated 
neutrophils (49).  In contrast, we have demonstrated that there was no increase in inflammatory 
cells in the livers of mice exposed for two weeks to the higher arsenic dose of 250 ppb (152).  
Since arsenic-induced defenestration is fully manifested within 2 weeks, these data suggested 
that arsenic directly affected the LSEC or surrounding cells to induce capillarization rather than a 
through a mechanism requiring leukocyte oxidase activity.  In the current study we used two 
independent strategies to test whether activating LSEC Nox2 oxidase was necessary and 
sufficient to effect phenotype change.   First, p47
phox
 is a canonical, essential cytosolic subunit of 
Nox2-based oxidase and the data demonstrate that genetic deletion of this subunit prevented 
arsenic-stimulated sinusoidal generation of nitrotyrosine (Figure 26),  loss of porosity (Figure 
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25A), and morphological changes in the space of Disse (Figure 25B).  Nitrotyrosnine staining 
co-localized with PECAM-1 positive LSEC.  Since superoxide is not capable of crossing cell 
membranes, this suggested that the LSEC were the source of superoxide or other reactive 
intermediates required to react with NO to form peroxynitrite.  Second, isolated LSECs were 
used to confirm that Nox2-based oxidase generated superoxide in response to arsenic exposure 
and that this superoxide or its derivatives were sufficient to cause the morphological changes 
indicative of capillarization.  The data indicated that in this isolated system, scavenging arsenic-
induced superoxide effectively prevented loss of scavenging activity, defenestration, and 
junctional PECAM-1 expression.  We used gp91ds-tat, an inhibitory peptide targeting Nox2 
interaction with p47phox, to implicate the Nox2-based oxidase as being the central mediator of 
the oxidant response to arsenic.  In contrast to the effects of the scrambled-tat peptide, in which 
the active targeting sequence in gp91ds-tat is re-arranged (Rey et al., 2001) (128), gp91ds-tat 
was completely effective in protecting the LSEC.  A final proof of the central role of the LSEC 
Nox2-based oxidase in arsenic signal was provided by the observation that preventing Rac1-
GTPase activity provided protection from arsenic-stimulated defenestration.  Rac1 GTPase is 
another essential component of the Nox2-based oxidase that provides an axis for enzyme 
stimulation in response to a number of endogenous ligands and environmental stimulants (104, 
163).  Thus, the data are consistent with LSEC Nox2-based oxidase directly contributing to 
endothelial dysfunction and suggest that this oxidase is the dominant isozyme for arsenic-
stimulated superoxide generation and capillarization. 
 
The data provide little support for a role of the other prevalent endothelial expressed 
isozyme, Nox4-based oxidase, in the response to arsenic, since this isoform does not require 
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p47
phox
 and thus should not be affected by either the p47
phox
 knockout or gp91ds-tat (125, 128).   
There is one in vitro report indicating that overexpression of constitutively active type 1 VEGF 
receptor in an immortalized sinusoidal endothelial cell line resulted in a six fold induction of 
Nox1, which increased apoptosis (87).  However, the cell line was not well characterized as 
retaining LSEC phenotype and Nox1 is generally expressed at low levels in endothelial cells 
(104, 125, 128).  The in vivo data in the current study do not rule out contributions of the Nox2 
oxidase in other liver cells, since stellate and Kupffer cells, as well as hepatocytes express the 
Nox2 anchor (127, 155).  Nonetheless, the ex vivo data confirm the necessary and sufficient role 
for LSEC Nox2-based oxidase in both capillarization and functional loss and additional oxidants 
from other liver cells would only add to this pathologic change in vivo.   
 
Arsenic-stimulated superoxide generation may promote defenestration and capillarization 
by quenching NO that is required for maintaining the fenestrated LSEC phenotype.   Fenestrated 
endothelium is found in tissues constitutively expressing high levels of VEGF and VEGF-
stimulated nitric oxide (108).  Deleve et al. demonstrated that the LSEC phenotype was 
maintained by paracrine stimulation through hepatocyte- and stellate cell-derived VEGF-
stimulated NO production in either the stellate or LSEC cells ) (46).  In reciprocal regulation, the 
LSEC NO suppresses stellate cell activation and collagen expression that facilitates fibrosis (45).   
Loss of NO contributes to pathogenic angiogenesis, fibrosis, and portal hypertension in the liver 
(90).   Peroxynitrite formed from the reaction of superoxide and NO has been proposed as a 
pathogenic mediator of liver perfusion defects caused by obesity and insulin resistance (20).  
Nitrosylation of protein tyrosine residues is a marker of peroxynitrite formation and the 
observation that arsenite failed to increase protein nitrosylation in p47
phox
 (-/-) mice (Figure 26) 
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suggests that stimulation of superoxide generation and peroxynitrite formation is a primary 
mechanism for arsenic-induced remodeling of the liver vasculature and impaired function in the 
sinusoids. The data do not discriminate, however, between the significance of superoxide 
depletion of regulatory NO or peroxynitrite-mediated signaling to arsenic-stimulated LSEC 
capillarization. 
 
While the functional consequences of arsenic-stimulated, oxidant-dependent signaling in 
LSEC are unique to this cell type, the initiation of this signaling may be common to endothelial 
cells in most vascular beds.  We observed that environmental exposures to arsenic stimulate 
angiogenesis in Matrigel plugs and tumor xenographs in vivo (147, 148), as well as tube 
formation by human microvascular cells in cultured Matrigel (84).  While the isoforms were not 
specifically identified, arsenic stimulated large vessel endothelial and smooth muscle cell NOXs 
(105, 145) and quenches bradykinin-stimulated NO generation in aortic endothelial cells (12) or 
NO dependent vasodilation in aortic rings (124).  In addition, endothelial peroxynitrite formation 
appears to contribute to arsenic-promoted atherosclerosis in genetic mouse models (24).  Thus, it 
is likely that the arsenic exposures in the current studies had systemic effects in most vascular 
beds.  However, few other pathological endpoints, such as atherosclerotic plaque formation, 
vessel wall thickening, or peripheral vascular disease would be expected to occur in a mouse 
within the 2 wk exposure period examined in the current studies.  Nonetheless, the importance of 
the LSEC- and liver-specific observations is that capillarization is a significant and relatively 
early pathogenic event.  Sustained capillarization and loss of LSEC scavenging may precede 
arsenic-promoted systemic disease or enhance deleterious systemic effects of arsenic by 
impairing clearance of acetylated lipids or modified proteins that are known risk factors for 
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vascular and metabolic disease.  Further studies are needed to determine whether the arsenic-
induced sinusoidal morphological changes and loss of LSEC scavenger function are initial steps 
in arsenic-induced vascular disease or are limited to pathogenic changes in the liver. 
  
The finding of morphological and functional changes in livers of mice exposed to 
concentrations of arsenic that promote human diseases other than cancer is significant, since 
mice are often several orders of magnitude less sensitive than humans to the carcinogenic and 
lethal effects of arsenic.  However, cardiovascular effects may be more sensitive disease 
endpoints in humans drinking the same levels of arsenic used in the current studies (31, 117, 
186) and the findings suggest that the mouse is an appropriate model for studying the etiology of 
arsenic-promoted disease.  In addition, these studies provide valuable information regarding gene 
environment interactions.  Hsueh et al. suggested that  genetic polymorphisms in the NOX p22 
subunit may contribute to arsenic-related hypertension in Taiwan (75).   
In summary, the current data support an essential for an NOX in a form of pathogenic 
vascular remodeling that can contribute liver diseases, as well as systemic hypertension and 
atherogenesis.  The Nox2-based oxidase in LSEC appears to be directly activated by 
environmental exposures to arsenic and this activation is central to arsenic-induced 
capillarization and loss of LSEC scavenging function.  The apparent requirement for Rac1-
GTPase activity (Figure 8) suggests that Rac1 and oxidase activation are downstream of the 
target of arsenic in the endothelial cells and that peroxynitrite formation may be a pathogenic 
endpoint of arsenic signaling in LSEC.  However, future experiments are needed to identify the 
molecular target(s) on endothelial cells that initiates arsenic signaling for oxidase activation.  
Identifying this target may reveal important pathogenic mechanisms promoting LSEC and 
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possibly systemic endothelial dysfunction that contribute to the etiology of environmentally-
derived vascular diseases. 
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6.1 ABSTRACT: 
Exposure to arsenic increases the risk for developing many vascular diseases, including 
liver vascular shunting, portal hypertension, and non-cirrohitc liver fibrosis.  However, the target 
that initiates these arsenic-related pathologies is unknown.  Given the rapid responses of vascular 
cells to arsenic, we hypothesized that signaling for these responses was receptor mediated.  Since 
arsenic-stimulated LSEC defenestration and capillarization is Rac1 and NOX dependent, we 
examined whether a GPCR upstream of Rac1 initiated these effects.  Pre-treatment of primary 
mouse LSECs with Pertussis toxin, an inhibitor of Gi/o, prevented arsenic-stimulated 
defenestration.   Since capillarization is a gain in barrier function, LSEC expression of the S1P1 
receptor, a major Gi/o linked regulator of endothelial barrier function, and its role in arsenic-
stimulated defenestration were investigated.  Immunofluorescence analysis of mouse livers 
demonstrated that S1P1was highly expressed in LSEC relative to large vessel endothelium.  In ex 
vivo studies, inhibiting LSEC S1P1 with a selective antagonist, VPC23109, blocked arsenic-
stimulated superoxide generation, defenestration, and PECAM-1 expression.  These results are 
the first to demonstrate that arsenic targets a specific LSEC GPCR to promote vascular 
remodeling, and the first demonstrating that S1P1 regulates oxidant-dependent LSEC 
capillarization. 
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6.2 INTRODUCTION: 
Drinking water contaminated with arsenic is a major public health concern that is 
estimated to affect more than 100 million people worldwide.  Ingestion of arsenic above the 
current MCL of 10 ppb  has been associated with an increased risk for developing cardiovascular 
diseases, lung diseases, hepatic diseases and cancers.  Even exposures at the current arsenic 
MCL, can stimulate vascular remodeling and pathogenic angiogenesis in vivo and ex vivo (147, 
149, 151, 152).  Based on epidemiological studies, arsenic exposed individuals are at greater risk 
for developing hypertension, cardiac arrthymias, atherosclerosis, and ischemic heart disease (31, 
75, 117, 185). Liver diseases that are highly associated with elevated arsenic in the drinking 
water include portal hypertension and non-cirrhotic liver fibrosis (110).  Despite the numerous 
diseases associated with arsenic, mechanistic understanding of how arsenic initiates pathogenic 
cell signaling is poorly understood. 
LSECs represent a unique endothelial cell population within the liver.  LSEC 
fenestrations, organized into sieve plates, are a dynamic filtration system that serves to filter 
lipoproteins, nutrients, and macromolecules from the blood stream. LSEC filtering is also 
facilitated by a lack of a basal lamina that allows free exchange between blood and hepatocytes 
to enhance oxygenation and increase metabolism of xenobiotics.  LSECs also function as a 
highly active scavenger receptor system significantly contributing to clearance of modified 
albumin, hyaluronin, and advance glycation end products from the blood (59, 109, 173, 183).  
Additional hallmarks of the normal LSEC phenotype include low surface expression of platelet 
endothelial cell adhesion molecule (PECAM-1), von Willebrand Factor, and caveolin-1.    
The maintenance of LSEC phenotype is a poorly understood process that requires both 
autocrine and paracrine cell signaling.   Constitutive expression of vascular endothelial cell 
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growth factor-stimulated nitric oxide cell signaling is required to maintain the fenestrated 
phenotype (46).   However, altered cell signaling, such as activation of NOX, can promote the 
loss of this phenotype; a process called capillarization.  Capillarization results in LSECs losing 
their fenestrations, developing a basement membrane, and increasing surface expression of 
PECAM-1. Many environmental and biological molecules, such as ethanol, oxidizing chemicals, 
and surfactants, as well as aging can promote the capillarization process (34, 35, 71, 73).  
Capillarization precedes both portal hypertension and liver fibrosis, therefore, possibly 
enhancing other systemic diseases including atherosclerosis, diabetes, and potentially metabolic 
disease.  Recently, arsenic was shown to promote mouse LSEC capillarization through an NOX-
dependent mechanism in both in vivo and ex vivo studies (151, 152).  
Since arsenic rapidly increases cultured endothelial cell Rac1 activity and NOX 
dependent generation of ROS to produce downstream signaling for angiogenic and remodeling 
responses (12, 13), we reasoned that arsenic initiates cell signaling amplification cascades that 
might be mediated through a receptor.  The following studies investigated this hypothesis by 
targeting the likely upstream activation of a GPCR upstream of Rac1 in the LSEC that regulates 
the morphological changes of defenestration and capillarization.  The results demonstrate that 
arsenic requires the S1P1 receptor, a major regulator of endothelial cell barrier function and 
angiogenesis to increase LSEC capillarization.  In addition the studies are the first to identify a 
role for S1P1 in promoting this important pathophysiological change in LSEC. 
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6.3 RESULTS: 
Gi/o containing g-protein complex activation is required for arsenic-stimulated 
capillarization.  Arsenic activates Rac1 to stimulate NOX  in cultured endothelial cells and in 
vivo (145, 151).  Activation of Rac1 through Gi is associated with many endothelial cell GPCR 
that link to angiogenesis and cell migration.  Therefore, we tested whether PTX, a selective Gi 
inhibitor was responsible for promoting LSEC defenestration.  As seen in Figure 30, arsenic 
stimulated LSEC defenestration, was inhibited using PTX.  Quantitative analysis of porosity seen 
in Figure 30 indicates that arsenic is primarily signaling through a Gi to promote LSEC 
defenestration.   
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          . 
Figure 30.  Arsenic stimulated defenestration is inhibited with PTX. 
Representative SEM images were captured from LSECs that were treated with PTX and arsenic 
for 8hrs.  Morphometric analysis was used to determine the percentage of open space (porosity) 
of five 10,000x images from five individual coverslips.   The graph represents the mean SD of 
sinusoidal porosity and significant differences were determined using a one-way ANOVA follow 
by a Newman Kuels post test.   
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S1P1/3 expression in SECs and total liver.  Many Gi coupled receptors link to Rac1 stimulation 
and NOX activity.  S1P1/3 are two such receptors on the surface of endothelial cells that can 
promote NOX activity and promote angiogenesis and vascular remodeling.  Therefore, we 
determined expression levels of S1P1/3 present on LSECs isolated from mice and total liver using 
immunofluorescene, RT-PCR, and western blot analysis. Qualitative immunofluorescent analysis 
confirmed that S1P1 was abundantly expressed and colocalized with PECAM-1 on LSECs in vivo 
(Figure 31A). However, S1P3 expression could not be detected (data not shown). Analysis of 
mRNA expression demonstrated abundant expression of S1P1 (Figure 31B). However, S1P3 
mRNA expression was relatively low in comparison to S1P1 and HPRT (Figure 31B). Western 
blot analysis also confirmed abundant levels of S1P1 expression in both total liver and isolated 
LSECs (Figure 31C).  To determine if arsenic effects protein expression of S1P1, mice were 
exposed to 100 ppb of arsenic for two weeks.   Western blot analysis demonstrated that S1P1 
protein expression is unaffected by arsenic (Figure 31C). Similarly, isolated LSECs exposed to 
arsenic for 8hrs also confirmed that S1P1 protein expression is not changed (Figure 31C). Taken 
together, these results demonstrate that S1P1 is highly expressed on LSECs, making it a potential 
target for arsenic stimulated defenestration.   
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Figure 31.  S1P1 mRNA and protein expression colocalizes is highly abundant on LSECs but 
does not change after arsenic exposure. 
A. Livers from mice exposed to 100ppb of arsenic were immunostained for S1P1 (Green 
Channel), PECAM (Red Channel) and nuclei (Blue Channel).  B.  RT-PCR analysis of S1P1  and 
S1P3 from total liver tissue and isolated LSECs. C. Total liver extract from mice exposed to 0 
and 100ppb of arsenic were immunoblotted for S1P1 and -actin.  C.  Primary LSECs isolated 
from mice were exposed to control or 2.5 M arsenic for 24 hours and western blot analysis was 
performed to determine S1P1 expression. 
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VPC23019 inhibits LSEC defenestration.  Arsenic activates a Gi linked GCPR to promote loss 
of fenestrae seen in Figure 32.  Since S1P1 is abundantly expressed on LSECs (not S1P3) and is 
linked to a Gi, we hypothesized that arsenic was signaling the S1P1 to promote defenestration.  
To test this hypothesis, we pre-incubated primary LSECs with VPC23019, a selective inhibitor 
of S1P1/3 1hr prior to arsenic exposure.  Figure 32 demonstrates that arsenic promotes a loss 
fenestrations, but is inhibited with VPC23019.  This data suggests that arsenic requires S1P1 on 
LSECs to promote loss of fenestrae. 
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Figure 32. VPC23019 limits arsenic-induced sinusoidal endothelial cell defenestration. 
 LSECs isolated from mice were preincubated with VPC23019 1hr prior to arsenic or S1P 
exposure.  Cells were treated with 2.5M arsenic for 8hrs and fixed for SEM analysis.  Five 
images taken from five individual coverslips were analyzed using Metamorph to determine the 
% of open space (porosity).  Data in the graph represents the mean SD of porosity of LSECs.  
Significance was obtained by using a one-way ANOVA followed by Newman Kuells post hoc 
test. 
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VPC23019 blocks PECAM-1 induction and DHE oxidation.  To further test whether arsenic is 
targeting S1P1 to promote LSEC capillarization,  primary LSECs were pre-treated with 
VPC23019, exposed to arsenic for 8hrs and immunostained for PECAM-1.  Results in Figure 33 
demonstrate that VPC23091 inhibits arsenic stimulated PECAM-1 expression.  This data further 
supports the fact that arsenic is targeting S1P1 to promote defenestration.  Previously, we have 
demonstrated that arsenic stimulates NOX2 to generate superoxide production leading to 
capillarization ex vivo and in vivo.  Therefore, we tested whether VPC23019 would block 
superoxide production in primary LSECs exposed to arsenic.  To do this, LSECs preloaded with 
5M DHE 10 minutes before arsenic exposure. Thirty minutes after adding arsenic, the cells 
were fixed and imaged for HE fluorescence relative to the fluorescence of Draq5 stained nuclei. 
Figure 33B indicates that VPC23019 limits superoxide production in LSECs suggesting that 
arsenic signals through S1P1 leading to superoxide generation. 
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Figure 33.  PECAM-1 surface expression and DHE oxidation are inhibited using VPC23019 
after arsenic exposure. 
Primary LSECs were harvested from mice and preincubated with VPC23019 for 1hr prior to 
arsenic exposure.  PECAM-1 expression was determined by exposing LSECs to arsenic for 8hrs 
and fixing for immunofluorescence. Metamorph analysis was used to determine the % of 
thresholded pixels of PECAM normalized to the % threshold pixels of nuclei.  The graph 
presents data of the mean SD of normalized PECAM-1 surface expression followed by a one 
way ANOVA and a Newman-Kuells post test.   LSECs were pretreated with DHE 15 minutes 
before arsenic exposure.  Cells were then exposed to arsenic from 30 minutes and fixed for 
immunoflurescent imaging and quantified as described above.  The graph represents the HE 
normalized to nuclei and data is presented as the mean SD and significance was obtained by a 
one-way ANOVA followed by a Newman Kuells post test.  
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6.4 DISCUSSION:   
Exposure to environmental arsenic through the drinking water increases the risk for the 
development of liver diseases including non-cirrhotic fibrosis and portal hypertension (110).  
Increased vascular channels and ateriovenous shunts are seen in individuals with these diseases, 
however recently arsenic has been demonstrated to promote mouse sinusoidal endothelial cell 
capillarization and vascular shunting in vivo and ex vivo (151, 152).  More recently, arsenic has 
been shown to activate LSEC NOX both ex vivo and in vivo to promote capillarization (Straub et 
al, Chapter 5).  However, how arsenic stimulates NOX activity and capillarization is unknown.  
In this study, we are first to demonstrate that arsenic requires Gi-linked S1P1 receptor to 
stimulate LSEC defenestration, increase surface expression of PECAM-1, and increases 
superoxide production ex vivo.   
NOX is an important enzyme required for many vascular cell responses including 
neovascularization, vessel remodeling, and angiogenesis in both endothelial cell and smooth 
muscle cells (104, 163). Many exogenous and exogenous factors have the ability to activate 
NOX including S1P (27).   Arsenic can stimulate NOX in large vessel endothelial cells and 
smooth muscle cells through the activation of the small GTPase Rac1 (105, 145).  Arsenic 
stimulates Rac1 to the membranes of capillarizaed LSECs in vivo and NOX mediates 
capillarization of LSECs ex vivo and in vivo (151).   Arsenic also targets the S1P1 receptor in 
human microvascular endothelial cells to stimulate Rac1 activity and pro-angiogenic and 
inflammatory gene expression as well as tube formation (Barchowsky 2008).  However, there are 
no reports identifying potential targets of arsenic on LSECS to activate NOX leading to 
endothelial cell dysfunction and remodeling.  Therefore, S1P1 was hypothesized to be a suitable 
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candidate for initiating arsenic signals since it is linked to barrier function and NOX both of 
which are regulated by Rac1.  
Membrane bound Rac1 GTPase and activation of NOX occur rapidly after exposure to 
arsenic in endothelial cells and smooth muscle cells mediating many downstream signaling and 
remodeling responses (105, 145).  Therefore, we tested whether a GPCR was required for LSEC 
capillarization ex vivo. Using the selective Gi/o inhibitor PTX, demonstration that arsenic signals 
through a Gi/o linked receptor(s) to promote LSEC defenestration was achieved.  These data 
suggest that any Gi/o coupled receptor that is linked to Rac1 GTPase and NOX could potentially 
promote capillarization. Since capillarization is a gain in barrier function, LSEC expression of 
the S1P1 receptor, a major Gi/o linked regulator of endothelial barrier function was hypothesized 
to play a role in arsenic stimulated capillarization.   
S1P is a biologically active sphingolipid that is critically involved in many physiological 
systems, including morphological regulation of both the cardiovascular and central nervous 
systems.  S1P mediates many biological responses including cytoskeletal organization and 
migration, tight junction assembly, proliferation, and barrier function (74, 94, 112).  S1P has five 
biologically active receptors that are GPCR termed as S1P1-5.  Expression of these receptors in 
the vasculature is limited to S1P1-3, where S1P1 is the most abundantly expressed S1P receptor 
on endothelial cells (reviewed in (19)).  Expression of S1P1 is highly abundant on LSECs in vivo 
and ex vivo and does not change expression levels after arsenic exposure Figure 31.  This data is 
consistent with our previous data demonstrating that arsenic does not change expression of S1P1. 
(Barchowsky 2008).   Consistent with this report, S1P3 expression was expressed at extremely 
low to undetectable levels (data not shown).  Given that the expression of S1P3 is extremely low, 
it is unlikely that arsenic stimulates capillarization through this receptor.   
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Genetic deletion of S1P1 is embryonic lethal with pronounced defects in angiogenesis, 
endothelial barrier function, and vascular tone (6, 7). Neither S1P2 nor S1P3 are embryonic lethal 
and their deletion does not show obvious phenotypes (88). S1P1 primarily couples through Gi/o, 
whereas S1P2 and S1P3 couple through Gi/o, Gq, and G12/13.  S1P1 activation of the Gi/o 
pathway has been associated with most of the biological responses of endothelial cells to S1P, 
especially those that contribute to cell spreading and barrier function (19, 85, 112).  
Alternatively, S1P3-mediated activation of Gq promoted phopholipase C pathways and G12/13 
activated Rho-associated kinase (ROCK) it inhibit migration, and reduce endothelial cell barrier 
function and induce constriction (154).  Therefore to test the hypothesis that S1P1 is required for 
arsenic stimulated capillarization ex vivo, LSECs were pretreated VPC23019 and exposed to 
arsenic.  These results demonstrate that S1P1 is required for arsenic mediated capillarization.  
Furthermore, this data also demonstrates that S1P is also capable of promoting capillarization.  
These data further supports S1P1 contributing role in endothelial cell spreading and barrier 
enhancement (19, 85, 112) but more importantly it demonstrates the pathological role S1P1 play 
in LSECs.     
In summary, these data are first to demonstrate that arsenic requires a Gi/o linked GPCR, 
specifically S1P1, to induce reactive oxygen cell signaling thereby stimulating capillarization and 
increased surface expression of PECAM-1.  These novel results reveal a specific receptor on 
LSECs in which arsenic can signal through, but also demonstrates that the S1P1 receptor can play 
a pathological for the development of capillarization and vascular remodeling.  Furthermore, 
mechanistic understanding of the role that S1P1 plays in arsenic stimulated vascular disease, will 
greatly aid in therapeutic intervention for individuals exposed to arsenic, but also impact on the 
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physiological and pathological understanding of the role S1P1 play in the LSECs and other 
vascular beds. 
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7.0  CHAPTER 7.  DISCUSSION  
7.1 CONCLUSIONS 
7.1.1 Arsenic and Liver Disease 
Despite the fact that arsenic is recognized as an ubiquitous element that poses significant 
health risks for cardiovascular diseases and cancers, the mechanisms through which arsenic 
initiates pathogenic signaling have not been resolved.  Liver disease, such as portal hypertension, 
non-cirrhotic portal fibrosis, and vascular shunting correlated with arsenic exposure through 
unknown mechanisms. The data presented in this thesis demonstrate possible mechanisms that 
explain the strong association between arsenic and liver disease.  The mechanisms involve the 
requirement of S1P1 receptor to activate NOX thereby promoting downstream cell signaling and 
LSEC capillarization.  Further applied and basic science studies are required to confirm that 
these pathways are involved in the pathogenesis of arsenic-induced liver disease.  Identifying 
these mechanisms advance the molecular understanding of pathological dysregulation of 
fenestrated endothelium as it relates to liver diseases and possibly arsenic-related systemic 
vascular changes.  This identification may also reveal targets for chemoprevention and therapies 
that limit environmentally derived vascular diseases caused by arsenic. 
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7.1.2 Arsenic Promotes Liver Vascular Remodeling in a Dose and Time Dependent 
Manner. 
 The vascular system is one of the most sensitive organ systems to arsenic.  One conflicting 
factor for determining safe drinking water consumption is dose.  The old MCL of 50 ppb and the 
new MCL of 10 ppb were set based on cancer risk.  However, this standard may not ensure 
public health safety, since cancer may not be the proper disease endpoint.  Moreover, little 
evidence supports the fact that arsenic is a carcinogen at low levels.  But rather, the 
cardiovascular system may be a better predictor of arsenic toxicity since many human and animal 
studies demonstrate molecular, cellular, and pathological changes after low dose arsenic 
exposure. For example, it is estimated that the previous MCL of 50 ppb may double the risk of 
developing hypertension after chronic exposure to arsenic (126).  This was recently confirmed by 
demonstrating significant increased risk of hypertension in humans exposed to 50 ppb of arsenic 
and below, especially in those individuals with poor nutritional status (32).   Animal studies have 
demonstrated that arsenic can enhance tumorgenesis by stimulating neovascularization, 
angiogenesis, and vascular remodeling (82, 147, 149) .  Despite these important findings, 
understanding the pathological mechanisms of arsenic-induced vascular disease within an 
endogenous bed has been poorly understood. The liver makes for a suitable model system since 
it is one of the first organs that arsenic targets, as well as the major organ that metabolizes 
arsenic.  The data in chapters 3 and 4 are the first demonstration that arsenic can promote 
pathological vascular remodeling within an endogenous bed, the liver.  These results extend our 
previous observations demonstrating that low levels of arsenic can promote vascular remodeling, 
neovascularization, and tumor angiogenesis in models of vascular development and tumors (147, 
149).   
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The data presented in this thesis differ significantly from the results obtained from 
previous rodent studies of arsenic effects on liver vasculature (14, 41, 61, 110).  The biggest 
difference in these studies was that moderate to low levels of arsenic (10-250 ppb) promoted 
LSEC capillarization, large vessel remodeling and vascular shunting.  Our studies used drinking 
water concentrations that would fit the demographic curve for arsenic-induced liver disease (250 
ppb or less= ~0.7-0.9µg/mouse/day for 5 weeks; human equivalent ~32µg/day for 3.75 years).  
More importantly, the data generated in Chapter 5 demonstrates that the current MCL of 10 ppb 
may not be adequate for protecting human health since pathological vascular remodeling occurs 
at such low concentrations. Therefore, the data in this thesis suggest more plausible mechanisms 
of arsenic-stimulated liver disease and cardiovascular disease since the cardiovascular system 
appears to be extremely sensitive to the effects of the metalloid.    
  
7.1.3 Arsenic-Stimulated Sinusoidal Endothelial Cell Capillarization. 
LSEC maturation and angiogenesis play significant roles in disruption of normal liver 
functions and contributes to multiple diseases (60, 114, 136, 162, 171).  Capillarization of 
LSECs is a prerequisite for the development of liver disease that includes portal hypertension 
and fibrosis (37, 46, 98).  The data in Chapters 3,4 and 5  are the first to demonstrate that human-
relevant arsenic exposures induce capillarization and remodels the liver vasculature in vivo and 
ex vivo in a time and dose dependent manner.  Data presented in Chapter 2 demonstrates that the 
vascular phenotypic changes in an endogenous bed appear to be a more sensitive biomarker for 
arsenic exposure than measuring total arsenic levels from liver tissue.  LSEC capillarization with 
a compensatory gain of caveolae represent potential mechanisms for arsenic to alter metabolism 
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and thereby contribute to other systemic vascular diseases such as atherosclerosis.     
Capillarization is the angiogenic process of the liver sinusoidal endothelium and is 
fundamentally different from angiogenesis in other vascular beds.  The main distinction is that 
there is no increase in vessel number due to the anatomic constraints of the liver sieve plates.  
Capillarization of LSEC results in ultrastructural phenotypic conversion to endothelial cells with 
tight intercellular junctions and loss of fenestrations (37, 51, 179).  Increased LSEC membrane 
PECAM-1 protein expression and deposition of a laminin-1-containing basement membrane are 
hallmarks of capillarization in injured livers (37, 46).  As demonstrated in Chapter 3, 4 and 5, 
arsenic induces these hallmarks as it promotes defenestration and capillarization of the LSEC.  
The time course for gain of PECAM-1 and laminin-1 is identical to the time course for loss of 
porosity (Chapter 4), indicating that these are reciprocal functions.  Thus, as the fenestrations 
close the cells increase intracellular contacts and transport through the fenestrations is limited by 
gain of a basement membrane.   
7.1.4 Potential Mechanisms of Arsenic-induced Liver Injury.  
Liver injury in response to arsenic has been proposed to be mediated by oxidative stress 
and increased levels of inflammatory cytokines (41, 110).  Das et al. showed that nine months 
was required before overt liver injury was observed in response to high levels of arsenic and that 
this injury was associated with increased oxidative damage and cytokine release (41).  
Capillarization has been shown to occur with aging, an effect that may be caused by progressive 
oxidative injury to LSEC (35, 73).  The data in Chapter 4 demonstrated that capillarization 
developed over 1-2 weeks of arsenic exposure and was greatly accelerated by arsenic compared 
to the natural decline in porosity seen in age matched controls.  Since arsenite stimulates oxidant 
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production by endothelial cell NOX (145), it is possible that chronic oxidant stress was 
responsible for arsenic-induced loss of porosity and phenotypic change in LSEC.  However, if 
this was true, the oxidative stress would have had to be at a low level since total liver 
hemoxygenase-1 mRNA levels increased by less than 3-fold in following exposure to 250 ppb of 
arsenite for 5 wks (data not shown).  The data in Chapter 4 argue that an inflammatory response 
resulted from arsenic-initiated capillarization instead of causing it.  Leukocytes were not 
recruited until after the maximal loss in LSEC porosity occurred.  Thus, leukocyte oxidant 
generation was unlikely to have contributed to arsenite-induced LSEC phenotypic change.  It is 
possible that the delayed increase in CD45 positive cell infiltration was the result of vessel 
maturation in the capillarization process rather than a direct effect of arsenic on leukocyte 
activity.    
 
7.1.5 Rac1 is Mobilized to the Plasma Membrane after Arsenic Exposure In Vivo. 
Superoxide generating NOX plays a fundamental role in angiogenesis, 
neovascularization, and vascular remodeling in endothelial and smooth muscle cells (104, 163). 
Arsenic stimulates oxidant production in large vessel endothelial cells by stimulating NOX 
activity (145).  The activation of NOX is mediated through an orchestrated mobilization of many 
proteins that are required for NOX activity including Rac1-GTPase.  The data in Chapter 3 
demonstrated that chronic exposure to arsenic mobilized Rac1 to the plasma membrane of 
LSECs in vivo.  These data indicated that arsenic could possibly promote chronic oxidant stress 
and/or endothelial cell spreading that supports capillarization in response to arsenic.   
 
 141 
7.1.6 Arsenic Stimulated NOX 2 Promotes LSEC Capillarization and Scavenger Receptor 
Loss 
The studies presented in Chapter 5 demonstrated that the mechanism for arsenite effects 
on the liver vasculature that involve pathologic stimulation of LSEC NOX.  Moreover, this is the 
first study showing that NOX2 promotes LSEC capillarization, a process that has been 
hypothesized to be oxidant mediated (20, 71). These data suggest that pathological activation of 
NOX2 is a fundamental mechanism for the etiology of arsenic-promoted hepatic and system 
diseases and has significant public health implications.  
There have been very few studies focusing on the contributing role NOX enzymes play in 
physiological and pathophysiological responses of LSECs to chemicals and environmental 
exposures.   Several adverse stimuli such as oxidants, surfactants, and oxidizing conditions can 
promote LSEC capillarization (34, 35).  Also, aging has been demonstrated to promote 
capillarization in both humans and rats to enhance circulating lipid and lipoprotein profiles. (73).  
Exposure to high levels of arsenic have been proposed to stimulate vascular-channeling and 
fibrosis in rats through the depletion of glutathione (61).  Data in Chapter 5 demonstrate that 
arsenic can promote LSEC capillarization through a NOX2 dependent pathway.  These data 
would argue with data in (61), since the shorter and lower level arsenic exposures  used in our 
studies would not be expected to deplete glutathione.  These data in Chapter 5 are consistent with 
our previous observations demonstrating that superoxide generating NOX can promotes vascular 
cell signaling but more importantly demonstrates that NOX2 can stimulate vascular cell 
remodeling within an endogenous bed (12, 145).  Also, this is one of the first demonstrations that 
capillarization is associated with scavenger receptor loss through a superoxide dependent 
mechanism.  However, the data in Chapter 5 do not rule out contributions of NOX2 in other liver 
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cells, since stellate and Kupffer cells, as well as hepatocytes contain NOX2 (127, 155) and 
participate in paracrine maintenance of the fenestrated or capilliarized LSEC phenotypes (20, 45, 
46).  Nonetheless, the ex vivo data confirm a functional role for NOX2 in LSEC capillarization 
and scavenger receptor loss in response to arsenic.   
7.1.7 Mechanism of Arsenic Stimulated Superoxide Stimulated Capillarization  
Arsenic stimulated NOX superoxide generation may promote defenestration, 
capillarization, and scavenger receptor loss by quenching NO that is required for maintenance of 
LSEC phenotype. Fenestrated endothelium is found in tissues constitutively expressing high 
levels of VEGF and VEGF-stimulated nitric oxide (108). Deleve et al. demonstrated that the 
LSEC phenotype was maintained by paracrine stimulation through hepatocyte- and stellate cell-
derived VEGF stimulated NO production in either the stellate or LSEC cells (46). In addition, 
loss of NO contributes to pathogenic angiogenesis, fibrosis, and portal hypertension in the liver 
(90).  Peroxynitrite formed from the reaction of superoxide and NO has been proposed as a 
pathogenic mediator of liver perfusion defects caused by obesity and insulin resistance (18). 
Arsenic generated superoxide was shown to quench bradykinin-stimulated nitric oxide in large 
vessel endothelial cells (12). In addition, endothelial peroxynitrite formation appears to 
contribute to arsenic-promoted atherosclerosis in genetic mouse models (24).   The data in 
Chapter 5 demonstrate increased nitrotyrosine staining that is colocalized with LSEC suggesting 
that peroxynitrite is being formed in LSECs.  However, arsenic signaling through superoxide has 
also been demonstrated to enhance hydrogen peroxide cell signaling (12).  Even though 
hydrogen peroxide was not measured, it may be possible that this signaling may occur along with 
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peroxynitrite signaling.  Further studies will need to be performed to determine specific 
downstream cell signaling for arsenic stimulated capillarization and scavenger receptor loss. 
The studies in Chapter 5 provide valuable information regarding gene environment 
interactions. Hsueh et al. (75) suggest that genetic polymorphisms in NOX may contribute to 
arsenic-related hypertension in Taiwan (8) and the current data confirm that NOX is required for 
a form of pathogenic vascular remodeling that can contribute to systemic hypertension and 
atherogenesis.  Future experiments are needed to translate findings from the data presented in 
Chapter 5 to human populations associated with liver disease and arsenic exposures.  Identifying 
these individuals should provide valuable basic information by revealing important pathogenic 
mechanisms promoting LSEC dysfunction that contributes to the etiology of environmentally-
derived vascular diseases. 
 
7.1.8 Gαi  and NOX Activation 
NOX is an important enzyme required for many vascular cell responses including 
neovascularization, vessel remodeling, and angiogenesis in both endothelial cell and smooth 
muscle cells (19, 32). Many exogenous and endogenous factors have the ability to activate NOX 
including S1P (6).   Arsenic can stimulate NOX in large vessel endothelial cells and smooth 
muscle cells through the activation of the small GTPase Rac1 (20, 26).  Arsenic stimulates Rac1 
to the membranes of capilliarized LSECs in vivo and NOX mediates capillarization of LSECs ex 
vivo and in vivo (29).   Recently, arsenic has been demonstrated to target the S1P1 receptor in 
human microvascular endothelial cells to stimulate Rac1 activity as well as pro-angiogenic and 
inflammatory gene expression as well as tube formation (unpublished data Barchowsky Lab).  
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However, there were no reports identifying potential targets of arsenic on LSECs to activate 
NOX leading to endothelial cell dysfunction and remodeling.  Therefore, S1P1 was hypothesized 
to be suitable candidate for arsenic since it is linked to barrier function and NOX both of which 
are regulated by Rac1.  
Membrane bound Rac1 GTPase and activation of NOX occur rapidly after exposure to 
arsenic in endothelial cells and smooth muscle cells mediating many downstream signaling and 
remodeling responses (20, 26).  Therefore, we tested whether a GPCR was required for LSEC 
capillarization ex vivo. Many Gi/o linked receptors are linked to Rac1 and NOX to promote 
increased barrier function and vascular remodeling in endothelial cells including S1P1 (23). Data 
in Chapter 6 demonstrated that arsenic stimulated capillarization is PTX sensitive.  These data 
are consistent with previous data demonstrating that S1P1 is required for arsenic-stimulated Rac1 
activity, elevated pro-angiogenic gene expression, and increased tube formation in human lung 
microvascular endothelial cells (unpublished Barchowsky Lab 2008).  Furthermore, these data 
suggest that any Gi/o coupled receptor that is linked to Rac1 GTPase and NOX could potentially 
promote capillarization. Since capillarization is a gain in barrier function, LSEC expression of 
the S1P1 receptor, a major Gi/o linked regulator of endothelial barrier function was hypothesized 
to play a role in arsenic stimulated capillarization.   
S1P is a biologically active sphingolipid that is critically involved in many physiological 
systems, including morphological regulation of both the cardiovascular and central nervous 
systems.    Expression of S1P1 is highly abundant on LSECs in vivo and ex vivo and does not 
change expression levels after arsenic exposure (Chapter 6).  These data are consistent with our 
previous data demonstrating that arsenic does not change expression of S1P1 in microvascular 
endothelial cells. (Barchowsky Lab 2008).   Consistent with this report, S1P3 expression was 
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expressed at extremely low to undetectable levels.  Given that the expression of S1P3 is 
extremely low and has not been demonstrated to stimulate Rac1 after arsenic exposure, it is 
unlikely that arsenic stimulates capillarization through this receptor.   
 
 
         
Figure 34.  S1P receptors and downstream signaling responses  
Adapted from (19). 
 
 
S1P1 activation of the Gi/o pathway has been associated with most of the biological 
responses of endothelial cells to S1P, especially those that contribute to cell spreading and 
barrier function (5, 16, 23) (Figure 34).  Alternatively, S1P3-mediated activation of Gq promoted 
phopholipase C pathways and G12/13 activated Rho-associated kinase (ROCK) it inhibit 
migration, and reduce endothelial cell barrier function and induce constriction (31).  Therefore to 
test the hypothesis that S1P1 is required for arsenic stimulated capillarization ex vivo, increased 
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PECAM-1 expression, and increased superoxide production, LSECs were pretreated VPC23019 
and exposed to arsenic.  Chapter 6 results demonstrate that S1P1 is required for arsenic-mediated 
capillarization, increased PECAM-1 expression, and superoxide increases.  Furthermore, this 
data also demonstrates that S1P is also capable of promoting capillarization.  This data further 
supports S1P1 contributing role in endothelial cell spreading and barrier enhancement (5, 16, 23) 
but more importantly it demonstrates the pathological role S1P1 play in LSECs.     
In summary, these data are the first demonstrating that arsenic requires a Gi/o linked 
GPCR, specifically S1P1, to induce reactive oxygen cell signaling thereby stimulating 
capillarization and increased surface expression of PECAM-1.  These novel results reveal a 
specific receptor on LSECs in which arsenic can signal through, but also demonstrates that the 
S1P1 receptor can play a pathological for the development of capillarization and vascular 
remodeling.  Furthermore, mechanistic understanding of the role that S1P1 plays in arsenic 
stimulated vascular disease, will greatly aid in therapeutic intervention for individuals exposed to 
arsenic, but also impact on the physiological and pathological understanding of the role S1P1 
play in the LSECs and other vascular beds. 
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Figure 35.  Schematic for Arsenic Stimulated Capillarization. 
1.) Arsenic requires S1P1 to promote superoxide generation and capillarization ex vivo. 
2.) Arsenic signals through NOX2 to promote superoxide generation and peroxynitrite 
formation ex vivo and in vivo. 
3.) Inhibition of NOX 2 limits capillarization and scavenger receptor loss ex vivo and in vivo. 
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7.1.9 Summary and Future Directions:  
In summary, these studies demonstrated that low levels of arsenic exposure can 
selectively stimulate pathological vascular remodeling within the liver through a S1P1 and 
NOX2 dependent mechanism (Figure 35).  Capillarization is a prerequisite for portal 
hypertension and liver fibrosis.  In vivo studies in this thesis demonstrated that low levels (10-
250 ppb) of arsenic can promote capillarization, increase PECAM-1 expression, and promote 
vascular shunting.  Pathological signaling through NOX2 is required to mediate arsenic-induced 
capillarization that was demonstrated ex vivo and in vivo.  Furthermore, novel observations 
demonstrated that S1P1 is required for arsenic stimulated superoxide generation and 
capillarization ex vivo.  Taken together, these studies provide valuable information that will aid 
in our understanding of arsenic-induced liver disease and potentially provide new and innovative 
strategies that will prevent and treat individuals exposed to arsenic. 
 Future directions of this work should include investigating local and system changes that 
occur after arsenic-induced capillarization. Changes such as lipid profiles, metabolic enzyme 
dysfunction and disease development should provide a solid basis for understanding the 
pathological role that capillarization plays in local and systemic disease development related to 
arsenic exposure. Furthermore, continuation of the S1P1 studies in vivo should provide more 
valuable information on the role S1P1 plays in the development of arsenic induced liver and 
vascular disease.  These continuing studies will harness new therapeutic strategies and targets 
that will combat and limit arsenic related diseases.   
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